Covered recipient · General Payments record
DAVID BERZ
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$85,243.80
138 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $55,031.95 | 22 |
| Honoraria | $13,700.00 | 5 |
| Travel and Lodging | $9,714.87 | 41 |
| Consulting Fee | $4,500.00 | 1 |
| Food and Beverage | $2,287.56 | 68 |
| Education | $9.42 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DAVID BERZ
NPI 1437375128 · CMS profile ID 110998
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
LOS ANGELES, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1437375128?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DAVID BERZ, NPI 1437375128, CMS profile ID 110998. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437375128?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). DAVID BERZ, NPI 1437375128, CMS profile ID 110998. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437375128?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- DAVID BERZ, NPI 1437375128, CMS profile ID 110998, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–138 of 138 matching records. This page contains 38 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1437375128?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
138 matching records · $85,243.80 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–138 of 138.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | $24.69 | 06/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848163599 | CMS |
| Amgen Inc. | $24.39 | 06/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825264487 | CMS |
| Karyopharm Therapeutics Inc. | $30.27 | 06/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845784377 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $20.75 | 06/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789065703 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $21.14 | 06/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 781008319 | CMS |
| Boehringer Ingelheim International GmbH | $119.48 | 06/04/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 822296013 | CMS |
| Boehringer Ingelheim International GmbH | $278.05 | 06/04/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 822296017 | CMS |
| AstraZeneca Pharmaceuticals LP | $268.85 | 05/26/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829361837 | CMS |
| AstraZeneca Pharmaceuticals LP | $121.67 | 05/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829525983 | CMS |
| AstraZeneca Pharmaceuticals LP | $947.37 | 05/26/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829978381 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $1,600.00 | 05/25/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851873515 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $19.75 | 05/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789085941 | CMS |
| Exelixis Inc. | $30.38 | 05/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838869193 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $9.42 | 05/12/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763334106 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $1,600.00 | 05/12/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851873513 | CMS |
| Merck Sharp & Dohme Corporation | $24.69 | 05/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848420183 | CMS |
| Genentech USA, Inc. | $23.25 | 05/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835903771 | CMS |
| AstraZeneca Pharmaceuticals LP | $250.00 | 05/04/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829969547 | CMS |
| JAZZ PHARMACEUTICALS INC. | $2,385.00 | 05/03/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845602665 | CMS |
| JAZZ PHARMACEUTICALS INC. | $3,710.00 | 04/26/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845606257 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $4,500.00 | 04/15/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851873511 | CMS |
| JAZZ PHARMACEUTICALS INC. | $122.92 | 04/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845603701 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.00 | 04/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829556117 | CMS |
| Daiichi Sankyo Inc. | $25.00 | 04/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836281177 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $21.81 | 03/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789068287 | CMS |
| Merck Sharp & Dohme Corporation | $48.16 | 03/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848463819 | CMS |
| Genentech USA, Inc. | $19.53 | 03/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835903767 | CMS |
| PUMA BIOTECHNOLOGY, INC. | $29.85 | 02/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834094253 | CMS |
| Boehringer Ingelheim International GmbH | $323.15 | 02/19/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 822295815 | CMS |
| JAZZ PHARMACEUTICALS INC. | $1,590.00 | 02/17/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845601695 | CMS |
| Genentech USA, Inc. | $24.38 | 02/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835903765 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $5,625.00 | 02/03/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851873519 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $161.00 | 01/20/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851873521 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $213.83 | 01/20/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851873523 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $96.36 | 01/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851873525 | CMS |
| Genentech USA, Inc. | $19.44 | 01/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835903761 | CMS |
| AstraZeneca Pharmaceuticals LP | $250.00 | 01/04/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829290241 | CMS |
| BeiGene USA, Inc. | $33.60 | 01/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 846699253 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,065.52 | 3 |
| PY2025 | Principal investigator | $22,570,156.96 | 3,127 |
| PY2024 | Principal investigator | $11,954,256.94 | 1,800 |
| PY2023 | Principal investigator | $4,769,303.07 | 1,104 |
| PY2022 | Principal investigator | $2,622,889.08 | 553 |
| PY2021 | Principal investigator | $743,277.94 | 102 |
| PY2020 | Principal investigator | $185,286.26 | 9 |
| PY2019 | Principal investigator | $60,123.89 | 5 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
3,130 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 12/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704453 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 12/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704455 |
| Principal investigator 1 | Incyte Corporation | $99.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611385 |
| Principal investigator 1 | Incyte Corporation | $4,131.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611407 |
| Principal investigator 1 | Incyte Corporation | $506.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611428 |
| Principal investigator 1 | Incyte Corporation | $107.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611462 |
| Principal investigator 1 | Incyte Corporation | $107.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611465 |
| Principal investigator 1 | Incyte Corporation | $107.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611469 |
| Principal investigator 1 | Incyte Corporation | $107.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611473 |
| Principal investigator 1 | Incyte Corporation | $58.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611501 |
| Principal investigator 1 | Incyte Corporation | $819.95 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611643 |
| Principal investigator 1 | Incyte Corporation | $80.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611730 |
| Principal investigator 1 | Incyte Corporation | $80.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611734 |
| Principal investigator 1 | Incyte Corporation | $80.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611740 |
| Principal investigator 1 | Incyte Corporation | $171.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611912 |
| Principal investigator 1 | Incyte Corporation | $171.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611919 |
| Principal investigator 1 | Incyte Corporation | $371.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611931 |
| Principal investigator 1 | Incyte Corporation | $2,351.70 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612294 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612385 |
| Principal investigator 1 | Incyte Corporation | $2,352.45 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612423 |
| Principal investigator 1 | Incyte Corporation | $242.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612512 |
| Principal investigator 1 | Incyte Corporation | $70.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612517 |
| Principal investigator 1 | Incyte Corporation | $70.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612519 |
| Principal investigator 1 | Incyte Corporation | $70.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612522 |
| Principal investigator 1 | Incyte Corporation | $63.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612580 |
| Principal investigator 1 | Incyte Corporation | $84.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612584 |
| Principal investigator 1 | Incyte Corporation | $84.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612587 |
| Principal investigator 1 | Incyte Corporation | $45.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612840 |
| Principal investigator 1 | Incyte Corporation | $1,845.95 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612858 |
| Principal investigator 1 | Incyte Corporation | $74.00 | 12/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612921 |
| Principal investigator 1 | ABBVIE INC. | $3,186.00 | 12/30/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202532256 |
| Principal investigator 1 | BeOne Medicines Ltd. | $11,756.07 | 12/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190336063 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $7,087.67 | 12/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220996852 |
| Principal investigator 1 | Incyte Corporation | $9,920.00 | 12/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611403 |
| Principal investigator 1 | Incyte Corporation | $3,051.00 | 12/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611720 |
| Principal investigator 1 | Incyte Corporation | $4,523.94 | 12/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611767 |
| Principal investigator 1 | Incyte Corporation | $1,845.00 | 12/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611937 |
| Principal investigator 1 | Incyte Corporation | $1,894.00 | 12/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611966 |
| Principal investigator 1 | Incyte Corporation | $2,978.00 | 12/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612005 |
| Principal investigator 1 | Incyte Corporation | $2,896.00 | 12/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612369 |
| Principal investigator 1 | Incyte Corporation | $3,487.00 | 12/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612395 |
| Principal investigator 1 | Incyte Corporation | $3,487.00 | 12/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612398 |
| Principal investigator 1 | Incyte Corporation | $6,278.00 | 12/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612407 |
| Principal investigator 1 | Incyte Corporation | $2,807.00 | 12/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612419 |
| Principal investigator 1 | Incyte Corporation | $2,079.18 | 12/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612464 |
| Principal investigator 1 | Incyte Corporation | $2,681.00 | 12/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612692 |
| Principal investigator 1 | Incyte Corporation | $2,681.00 | 12/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612697 |
| Principal investigator 1 | Incyte Corporation | $4,242.00 | 12/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612708 |
| Principal investigator 1 | Incyte Corporation | $2,090.00 | 12/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612862 |
| Principal investigator 1 | Incyte Corporation | $3,187.00 | 12/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612868 |
| Principal investigator 1 | Incyte Corporation | $769.57 | 12/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612887 |
| Principal investigator 1 | Janssen Research & Development, LLC | $80,688.00 | 12/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175413910 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $1,004,440.00 | 12/29/2025 | Non-covered Recipient Entity Valkyrie Global, Inc. | An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1232932041 |
| Principal investigator 1 | Janssen Research & Development, LLC | $99,009.00 | 12/26/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175413845 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,500.00 | 12/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175413815 |
| Principal investigator 1 | ABBVIE INC. | $379.62 | 12/23/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202531766 |
| Principal investigator 1 | ABBVIE INC. | $175.19 | 12/23/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202531768 |
| Principal investigator 1 | ABBVIE INC. | $167.22 | 12/23/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202531770 |
| Principal investigator 1 | ABBVIE INC. | $421.97 | 12/23/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202531844 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $177.00 | 12/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389771 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 12/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389785 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 12/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389815 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 12/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389823 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 12/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175413960 |
| Principal investigator 1 | PFIZER INC. | $24,273.44 | 12/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228715313 |
| Principal investigator 1 | BioNTech SE | $2,849.00 | 12/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012697 |
| Principal investigator 1 | BioNTech SE | $4,213.00 | 12/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012705 |
| Principal investigator 1 | BioNTech SE | $2,849.00 | 12/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012747 |
| Principal investigator 1 | BioNTech SE | $4,213.00 | 12/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012869 |
| Principal investigator 1 | BioNTech SE | $3,931.00 | 12/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012877 |
| Principal investigator 1 | BioNTech SE | $324.00 | 12/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012889 |
| Principal investigator 1 | Genentech, Inc. | $13,370.00 | 12/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211682018 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,709.55 | 12/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804796 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,709.55 | 12/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804798 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $21,942.90 | 12/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804800 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,709.55 | 12/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804802 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,615.00 | 12/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804804 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,709.55 | 12/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804806 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17,093.70 | 12/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804808 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11,253.70 | 12/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804811 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $185.00 | 12/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388413 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,801.00 | 12/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388431 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $675.00 | 12/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388435 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,801.00 | 12/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388453 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $405.00 | 12/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388459 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 12/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388483 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $185.00 | 12/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388493 |
| Principal investigator 1 | PFIZER INC. | $2,000.00 | 12/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228715243 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $254.55 | 12/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220996822 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $186.56 | 12/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220996824 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $159.84 | 12/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220996826 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $25.50 | 12/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220996828 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $14,515.85 | 12/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220996854 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $641.00 | 12/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388481 |
| Principal investigator 1 | Incyte Corporation | $222.86 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611399 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611508 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611511 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611515 |
| Principal investigator 1 | Incyte Corporation | $750.00 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611562 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611581 |
| Principal investigator 1 | Incyte Corporation | $900.00 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611616 |
| Principal investigator 1 | Incyte Corporation | $6,449.14 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611629 |
| Principal investigator 1 | Incyte Corporation | $3,561.12 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611665 |
| Principal investigator 1 | Incyte Corporation | $4,523.94 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611873 |
| Principal investigator 1 | Incyte Corporation | $4,523.94 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611877 |
| Principal investigator 1 | Incyte Corporation | $4,523.94 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611882 |
| Principal investigator 1 | Incyte Corporation | $4,523.94 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611885 |
| Principal investigator 1 | Incyte Corporation | $5,494.96 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611934 |
| Principal investigator 1 | Incyte Corporation | $175.00 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611978 |
| Principal investigator 1 | Incyte Corporation | $1,200.00 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611993 |
| Principal investigator 1 | Incyte Corporation | $600.00 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612015 |
| Principal investigator 1 | Incyte Corporation | $6,465.97 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612097 |
| Principal investigator 1 | Incyte Corporation | $6,465.97 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612100 |
| Principal investigator 1 | Incyte Corporation | $6,465.97 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612104 |
| Principal investigator 1 | Incyte Corporation | $6,465.97 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612108 |
| Principal investigator 1 | Incyte Corporation | $3,552.94 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612134 |
| Principal investigator 1 | Incyte Corporation | $3,552.94 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612139 |
| Principal investigator 1 | Incyte Corporation | $3,552.94 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612143 |
| Principal investigator 1 | Incyte Corporation | $3,552.94 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612147 |
| Principal investigator 1 | Incyte Corporation | $4,523.96 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612151 |
| Principal investigator 1 | Incyte Corporation | $4,523.96 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612154 |
| Principal investigator 1 | Incyte Corporation | $877.72 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612220 |
| Principal investigator 1 | Incyte Corporation | $350.00 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612286 |
| Principal investigator 1 | Incyte Corporation | $4,507.11 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612353 |
| Principal investigator 1 | Incyte Corporation | $4,507.11 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612356 |
| Principal investigator 1 | Incyte Corporation | $4,507.11 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612360 |
| Principal investigator 1 | Incyte Corporation | $4,507.11 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612366 |
| Principal investigator 1 | Incyte Corporation | $60.00 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612377 |
| Principal investigator 1 | Incyte Corporation | $60.00 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612381 |
| Principal investigator 1 | Incyte Corporation | $250.00 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612471 |
| Principal investigator 1 | Incyte Corporation | $210.00 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612543 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612550 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612555 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612560 |
| Principal investigator 1 | Incyte Corporation | $4,534.88 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612563 |
| Principal investigator 1 | Incyte Corporation | $429.73 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612571 |
| Principal investigator 1 | Incyte Corporation | $110.00 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612637 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612750 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612753 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612757 |
| Principal investigator 1 | Incyte Corporation | $4,533.12 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612783 |
| Principal investigator 1 | Incyte Corporation | $4,533.12 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612787 |
| Principal investigator 1 | Incyte Corporation | $4,533.12 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612791 |
| Principal investigator 1 | Incyte Corporation | $5,675.00 | 12/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612855 |
| Principal investigator 1 | BeOne Medicines Ltd. | $12,349.07 | 12/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190336054 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $8,859.59 | 12/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220996850 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $81,860.85 | 12/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220996884 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,688.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704137 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,050.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704139 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,350.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704141 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,400.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704143 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,300.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704145 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17,705.25 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804967 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17,689.05 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804969 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19,941.53 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805643 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,734.53 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805645 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,250.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | An open label trial of BI 765063 in combination with BI 754091 (ezabenlimab) alone or with BI 836880, chemotherapy, or cetuximab, in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or hepatocellular carcinoma (HCC) | No dispute reported | 06/30/2026 | 1220805649 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,250.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | An open label trial of BI 765063 in combination with BI 754091 (ezabenlimab) alone or with BI 836880, chemotherapy, or cetuximab, in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or hepatocellular carcinoma (HCC) | No dispute reported | 06/30/2026 | 1220805651 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,038.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | An open label trial of BI 765063 in combination with BI 754091 (ezabenlimab) alone or with BI 836880, chemotherapy, or cetuximab, in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or hepatocellular carcinoma (HCC) | No dispute reported | 06/30/2026 | 1220805653 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,000.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | An open label trial of BI 765063 in combination with BI 754091 (ezabenlimab) alone or with BI 836880, chemotherapy, or cetuximab, in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or hepatocellular carcinoma (HCC) | No dispute reported | 06/30/2026 | 1220805655 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,500.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | An open label trial of BI 765063 in combination with BI 754091 (ezabenlimab) alone or with BI 836880, chemotherapy, or cetuximab, in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or hepatocellular carcinoma (HCC) | No dispute reported | 06/30/2026 | 1220805657 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,175.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805797 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389757 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $540.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389765 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $84.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389773 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $154.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389775 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $32.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389777 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $57.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389779 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $205.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389795 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $72.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389797 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389801 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $100.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389809 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $81.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389811 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $58.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389813 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $105.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389819 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 12/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389821 |
| Principal investigator 1 | Genentech, Inc. | $4,691.40 | 12/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211682016 |
| Principal investigator 1 | Genentech, Inc. | $4,421.80 | 12/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211682020 |
| Principal investigator 1 | Genentech, Inc. | $20,098.32 | 12/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211682024 |
| Principal investigator 1 | Genentech, Inc. | $5,911.37 | 12/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211682026 |
| Principal investigator 1 | Genentech, Inc. | $20,028.00 | 12/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211682028 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 12/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175413773 |
| Principal investigator 1 | BioNTech SE | $34.00 | 12/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012767 |
| Principal investigator 1 | BioNTech SE | $77.00 | 12/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012771 |
| Principal investigator 1 | BioNTech SE | $214.00 | 12/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012773 |
| Principal investigator 1 | BioNTech SE | $34.00 | 12/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012775 |
| Principal investigator 1 | BioNTech SE | $154.00 | 12/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012805 |
| Principal investigator 1 | BioNTech SE | $101.00 | 12/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012807 |
| Principal investigator 1 | BioNTech SE | $77.00 | 12/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012809 |
| Principal investigator 1 | BioNTech SE | $6,647.00 | 12/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013063 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 12/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389791 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,013.00 | 12/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389803 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 12/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389817 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 12/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389827 |
| Principal investigator 1 | Incyte Corporation | $368.00 | 12/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240611505 |
| Principal investigator 1 | Incyte Corporation | $700.00 | 12/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611538 |
| Principal investigator 1 | Incyte Corporation | $440.00 | 12/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611743 |
| Principal investigator 1 | Incyte Corporation | $480.00 | 12/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611975 |
| Principal investigator 1 | Incyte Corporation | $840.00 | 12/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612112 |
| Principal investigator 1 | Incyte Corporation | $1,400.00 | 12/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612124 |
| Principal investigator 1 | Incyte Corporation | $750.00 | 12/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612129 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 12/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612373 |
| Principal investigator 1 | Incyte Corporation | $600.00 | 12/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240612426 |
| Principal investigator 1 | Incyte Corporation | $600.00 | 12/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240612431 |
| Principal investigator 1 | Incyte Corporation | $600.00 | 12/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240612435 |
| Principal investigator 1 | Incyte Corporation | $1,688.00 | 12/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612712 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 12/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240612741 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 12/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240612746 |
| Principal investigator 1 | BioNTech SE | $675.00 | 12/11/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012693 |
| Principal investigator 1 | BioNTech SE | $574.00 | 12/11/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012701 |
| Principal investigator 1 | BioNTech SE | $135.00 | 12/11/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012867 |
| Principal investigator 1 | BioNTech SE | $77.00 | 12/11/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012887 |
| Principal investigator 1 | BioNTech SE | $2,835.00 | 12/11/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012891 |
| Principal investigator 1 | BioNTech SE | $203.00 | 12/11/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012893 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $793.00 | 12/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805781 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,000.00 | 12/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805783 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $386.60 | 12/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805785 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,641.00 | 12/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805787 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,625.00 | 12/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805789 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,175.00 | 12/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805791 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,450.00 | 12/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805793 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,175.00 | 12/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805795 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $131,253.74 | 12/11/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184274376 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $15,391.35 | 12/11/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184274380 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,428.00 | 12/11/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184274382 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,121.55 | 12/11/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184274384 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $185.00 | 12/11/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184274386 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $296.45 | 12/11/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184274388 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $81.87 | 12/11/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184274390 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $23.11 | 12/11/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184274392 |
| Principal investigator 1 | ABBVIE INC. | $456.50 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202529858 |
| Principal investigator 1 | ABBVIE INC. | $489.23 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202529860 |
| Principal investigator 1 | ABBVIE INC. | $367.07 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202529862 |
| Principal investigator 1 | ABBVIE INC. | $587.40 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202529930 |
| Principal investigator 1 | ABBVIE INC. | $603.76 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202529932 |
| Principal investigator 1 | BeOne Medicines Ltd. | $260.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190329249 |
| Principal investigator 1 | BeOne Medicines Ltd. | $118.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190329311 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,600.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334493 |
| Principal investigator 1 | BeOne Medicines Ltd. | $4,550.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334509 |
| Principal investigator 1 | BeOne Medicines Ltd. | $52.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334533 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,250.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334541 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,300.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334545 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,543.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334558 |
| Principal investigator 1 | BeOne Medicines Ltd. | $260.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334610 |
| Principal investigator 1 | BeOne Medicines Ltd. | $4,680.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334655 |
| Principal investigator 1 | BeOne Medicines Ltd. | $192.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334659 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,300.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334671 |
| Principal investigator 1 | BeOne Medicines Ltd. | $260.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334703 |
| Principal investigator 1 | BeOne Medicines Ltd. | $230.31 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334711 |
| Principal investigator 1 | BeOne Medicines Ltd. | $195.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334723 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,138.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334743 |
| Principal investigator 1 | BeOne Medicines Ltd. | $234.70 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334759 |
| Principal investigator 1 | BeOne Medicines Ltd. | $65.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334767 |
| Principal investigator 1 | BeOne Medicines Ltd. | $650.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334779 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,950.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334797 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,950.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334809 |
| Principal investigator 1 | BeOne Medicines Ltd. | $65.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334848 |
| Principal investigator 1 | BeOne Medicines Ltd. | $94,320.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190337093 |
| Principal investigator 1 | BeOne Medicines Ltd. | $241.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190341606 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,500.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804794 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,965.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805637 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,991.25 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805639 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,400.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805641 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,439.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805815 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,439.00 | 12/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805817 |
| Principal investigator 1 | Incyte Corporation | $2,275.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240611432 |
| Principal investigator 1 | Incyte Corporation | $2,275.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240611436 |
| Principal investigator 1 | Incyte Corporation | $2,915.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240611775 |
| Principal investigator 1 | Incyte Corporation | $2,915.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240611779 |
| Principal investigator 1 | Incyte Corporation | $6,863.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240611795 |
| Principal investigator 1 | Incyte Corporation | $6,863.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240611797 |
| Principal investigator 1 | Incyte Corporation | $6,863.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240611800 |
| Principal investigator 1 | Incyte Corporation | $6,863.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240611805 |
| Principal investigator 1 | Incyte Corporation | $6,863.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240611809 |
| Principal investigator 1 | Incyte Corporation | $4,830.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240611900 |
| Principal investigator 1 | Incyte Corporation | $7,925.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240611946 |
| Principal investigator 1 | Incyte Corporation | $7,925.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240611950 |
| Principal investigator 1 | Incyte Corporation | $7,925.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240611953 |
| Principal investigator 1 | Incyte Corporation | $7,011.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240612178 |
| Principal investigator 1 | Incyte Corporation | $7,011.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240612182 |
| Principal investigator 1 | Incyte Corporation | $7,011.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240612186 |
| Principal investigator 1 | Incyte Corporation | $4,759.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240612223 |
| Principal investigator 1 | Incyte Corporation | $4,759.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240612227 |
| Principal investigator 1 | Incyte Corporation | $4,759.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240612231 |
| Principal investigator 1 | Incyte Corporation | $2,072.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240612452 |
| Principal investigator 1 | Incyte Corporation | $2,072.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240612456 |
| Principal investigator 1 | Incyte Corporation | $2,072.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240612459 |
| Principal investigator 1 | Incyte Corporation | $7,748.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240612720 |
| Principal investigator 1 | Incyte Corporation | $7,748.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240612723 |
| Principal investigator 1 | Incyte Corporation | $7,748.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240612727 |
| Principal investigator 1 | Incyte Corporation | $7,748.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240612730 |
| Principal investigator 1 | Incyte Corporation | $2,477.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240612828 |
| Principal investigator 1 | Incyte Corporation | $2,477.00 | 12/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors. | No dispute reported | 06/30/2026 | 1240612831 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $17,554.39 | 12/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220996886 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,500.00 | 12/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804792 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,758.00 | 12/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804955 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22,176.00 | 12/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804957 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,516.00 | 12/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804959 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,516.00 | 12/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804961 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,000.00 | 12/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804963 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,500.00 | 12/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804965 |
| Principal investigator 1 | Genentech, Inc. | $250.00 | 12/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL | No dispute reported | 06/30/2026 | 1211681958 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,376.00 | 12/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389759 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,250.00 | 12/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389763 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $405.21 | 12/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389767 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $529.92 | 12/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389783 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,519.00 | 12/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220804819 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,519.00 | 12/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220804821 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,500.00 | 12/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220804823 |
| Principal investigator 1 | Incyte Corporation | $18,250.30 | 12/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611714 |
| Principal investigator 1 | Incyte Corporation | $600.00 | 12/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611963 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 12/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175413916 |
| Principal investigator 1 | ABBVIE INC. | $26,662.50 | 12/04/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202528020 |
| Principal investigator 1 | ABBVIE INC. | $23,698.58 | 12/04/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202528422 |
| Principal investigator 1 | ABBVIE INC. | $4,538.84 | 12/04/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202529146 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 12/04/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175414018 |
| Principal investigator 1 | BioNTech SE | $101.00 | 12/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012769 |
| Principal investigator 1 | BioNTech SE | $176.00 | 12/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012783 |
| Principal investigator 1 | BioNTech SE | $70.00 | 12/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012785 |
| Principal investigator 1 | BioNTech SE | $109.00 | 12/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012787 |
| Principal investigator 1 | BioNTech SE | $63.00 | 12/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012789 |
| Principal investigator 1 | BioNTech SE | $101.00 | 12/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012791 |
| Principal investigator 1 | BioNTech SE | $39.00 | 12/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012793 |
| Principal investigator 1 | BioNTech SE | $69.00 | 12/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012795 |
| Principal investigator 1 | BioNTech SE | $163.00 | 12/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012797 |
| Principal investigator 1 | BioNTech SE | $84.00 | 12/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012799 |
| Principal investigator 1 | BioNTech SE | $46.00 | 12/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012801 |
| Principal investigator 1 | BioNTech SE | $405.00 | 12/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012803 |
| Principal investigator 1 | BioNTech SE | $149.00 | 12/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013061 |
| Principal investigator 1 | BioNTech SE | $5,166.00 | 12/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013067 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $14,515.85 | 12/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220996856 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 12/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577748 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 12/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577750 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 12/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704135 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704199 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704201 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $41,674.00 | 12/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804790 |
| Principal investigator 1 | Genentech, Inc. | $56.80 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211682014 |
| Principal investigator 1 | Genentech, Inc. | $1,099.98 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211682022 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611392 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611395 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611410 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611415 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611419 |
| Principal investigator 1 | Incyte Corporation | $184.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611441 |
| Principal investigator 1 | Incyte Corporation | $171.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611445 |
| Principal investigator 1 | Incyte Corporation | $171.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611449 |
| Principal investigator 1 | Incyte Corporation | $171.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611454 |
| Principal investigator 1 | Incyte Corporation | $4,131.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611625 |
| Principal investigator 1 | Incyte Corporation | $80.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611723 |
| Principal investigator 1 | Incyte Corporation | $80.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611727 |
| Principal investigator 1 | Incyte Corporation | $107.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611756 |
| Principal investigator 1 | Incyte Corporation | $2,351.70 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611833 |
| Principal investigator 1 | Incyte Corporation | $58.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611835 |
| Principal investigator 1 | Incyte Corporation | $58.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611840 |
| Principal investigator 1 | Incyte Corporation | $99.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611844 |
| Principal investigator 1 | Incyte Corporation | $63.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611998 |
| Principal investigator 1 | Incyte Corporation | $63.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612002 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612028 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612036 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612040 |
| Principal investigator 1 | Incyte Corporation | $70.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612043 |
| Principal investigator 1 | Incyte Corporation | $70.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612047 |
| Principal investigator 1 | Incyte Corporation | $70.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612050 |
| Principal investigator 1 | Incyte Corporation | $70.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612054 |
| Principal investigator 1 | Incyte Corporation | $70.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612058 |
| Principal investigator 1 | Incyte Corporation | $70.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612061 |
| Principal investigator 1 | Incyte Corporation | $45.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612415 |
| Principal investigator 1 | Incyte Corporation | $376.65 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612509 |
| Principal investigator 1 | Incyte Corporation | $1,744.70 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612567 |
| Principal investigator 1 | Incyte Corporation | $675.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612619 |
| Principal investigator 1 | Incyte Corporation | $65.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612629 |
| Principal investigator 1 | Incyte Corporation | $65.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612633 |
| Principal investigator 1 | Incyte Corporation | $242.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612649 |
| Principal investigator 1 | Incyte Corporation | $242.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612652 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612681 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612684 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612689 |
| Principal investigator 1 | Incyte Corporation | $750.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612734 |
| Principal investigator 1 | Incyte Corporation | $74.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612775 |
| Principal investigator 1 | Incyte Corporation | $74.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612780 |
| Principal investigator 1 | Incyte Corporation | $371.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612893 |
| Principal investigator 1 | Incyte Corporation | $84.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612896 |
| Principal investigator 1 | Incyte Corporation | $84.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612900 |
| Principal investigator 1 | Incyte Corporation | $84.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612904 |
| Principal investigator 1 | Incyte Corporation | $84.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612907 |
| Principal investigator 1 | Incyte Corporation | $84.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612911 |
| Principal investigator 1 | Incyte Corporation | $84.00 | 12/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612918 |
| Principal investigator 1 | PFIZER INC. | $24,273.44 | 12/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228715131 |
| Principal investigator 1 | PFIZER INC. | $2,000.00 | 12/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228715311 |
| Principal investigator 1 | PFIZER INC. | $28,297.52 | 12/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228715413 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 11/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704449 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 11/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704451 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $81,860.85 | 11/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220996880 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $5,279.04 | 11/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220996882 |
| Principal investigator 1 | Incyte Corporation | $70.00 | 11/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611371 |
| Principal investigator 1 | Incyte Corporation | $70.00 | 11/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611375 |
| Principal investigator 1 | Incyte Corporation | $70.00 | 11/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611379 |
| Principal investigator 1 | Incyte Corporation | $123.00 | 11/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611423 |
| Principal investigator 1 | Incyte Corporation | $80.00 | 11/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611531 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611535 |
| Principal investigator 1 | Incyte Corporation | $162.00 | 11/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611709 |
| Principal investigator 1 | Incyte Corporation | $58.00 | 11/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611760 |
| Principal investigator 1 | Incyte Corporation | $65.00 | 11/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611763 |
| Principal investigator 1 | Incyte Corporation | $63.00 | 11/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611959 |
| Principal investigator 1 | Incyte Corporation | $84.00 | 11/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612272 |
| Principal investigator 1 | Incyte Corporation | $84.00 | 11/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612276 |
| Principal investigator 1 | Incyte Corporation | $242.00 | 11/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612797 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,000.00 | 11/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175413840 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16,097.00 | 11/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804953 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $43,050.58 | 11/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | An open label trial of BI 765063 in combination with BI 754091 (ezabenlimab) alone or with BI 836880, chemotherapy, or cetuximab, in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) or hepatocellular carcinoma (HCC) | No dispute reported | 06/30/2026 | 1220805647 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $26,405.00 | 11/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805813 |
| Principal investigator 1 | Incyte Corporation | $123.42 | 11/26/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612547 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,460.25 | 11/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805811 |
| Principal investigator 1 | Genentech, Inc. | $125,191.00 | 11/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL | No dispute reported | 06/30/2026 | 1211681956 |
| Principal investigator 1 | BioNTech SE | $77.00 | 11/24/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012777 |
| Principal investigator 1 | BioNTech SE | $50.00 | 11/24/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012779 |
| Principal investigator 1 | BioNTech SE | $101.00 | 11/24/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012781 |
| Principal investigator 1 | BioNTech SE | $5,166.45 | 11/24/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013065 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $756.97 | 11/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805777 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $296.60 | 11/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805779 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $498.35 | 11/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805809 |
| Principal investigator 1 | Janssen Research & Development, LLC | $289.67 | 11/24/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175413723 |
| Principal investigator 1 | Janssen Research & Development, LLC | $277.55 | 11/24/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175413737 |
| Principal investigator 1 | Janssen Research & Development, LLC | $350.00 | 11/24/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175413768 |
| Principal investigator 1 | Janssen Research & Development, LLC | $350.00 | 11/24/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175413851 |
| Principal investigator 1 | Janssen Research & Development, LLC | $335.82 | 11/24/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175413858 |
| Principal investigator 1 | Janssen Research & Development, LLC | $350.00 | 11/24/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175413866 |
| Principal investigator 1 | Janssen Research & Development, LLC | $350.00 | 11/24/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175414024 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $790.00 | 11/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704103 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,510.00 | 11/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704107 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,210.00 | 11/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704109 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $380.00 | 11/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704111 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $990.00 | 11/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704113 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $725.00 | 11/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704115 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,777.00 | 11/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704117 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,429.10 | 11/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805799 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,429.10 | 11/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805801 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,382.10 | 11/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805803 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,449.10 | 11/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805805 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,178.25 | 11/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805807 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $72.00 | 11/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388451 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $205.00 | 11/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388463 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 11/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388469 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $52.48 | 11/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388479 |
| Principal investigator 1 | ABBVIE INC. | $14,735.00 | 11/20/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202524982 |
| Principal investigator 1 | ABBVIE INC. | $421.97 | 11/20/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202524984 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,860.00 | 11/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334715 |
| Principal investigator 1 | BeOne Medicines Ltd. | $4,364.00 | 11/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334819 |
| Principal investigator 1 | BeOne Medicines Ltd. | $4,364.00 | 11/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334851 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,549.00 | 11/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190341610 |
| Principal investigator 1 | Janssen Research & Development, LLC | $49,869.00 | 11/19/2025 | Non-covered Recipient Entity Beverly Hills Cancer Ctr | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175167450 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22,700.00 | 11/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805775 |
| Principal investigator 1 | Incyte Corporation | $210.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611383 |
| Principal investigator 1 | Incyte Corporation | $2,150.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611389 |
| Principal investigator 1 | Incyte Corporation | $1,250.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611543 |
| Principal investigator 1 | Incyte Corporation | $2,200.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611566 |
| Principal investigator 1 | Incyte Corporation | $3,000.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611613 |
| Principal investigator 1 | Incyte Corporation | $11,350.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611640 |
| Principal investigator 1 | Incyte Corporation | $17,500.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611770 |
| Principal investigator 1 | Incyte Corporation | $110.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612264 |
| Principal investigator 1 | Incyte Corporation | $60.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612317 |
| Principal investigator 1 | Incyte Corporation | $60.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612322 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612326 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612330 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612334 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612338 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612343 |
| Principal investigator 1 | Incyte Corporation | $1.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612391 |
| Principal investigator 1 | Incyte Corporation | $175.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612438 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612443 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612447 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612489 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612493 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612498 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612502 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612505 |
| Principal investigator 1 | Incyte Corporation | $250.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612771 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612801 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612805 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612811 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612814 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612816 |
| Principal investigator 1 | Incyte Corporation | $5,675.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612820 |
| Principal investigator 1 | Incyte Corporation | $5,675.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612824 |
| Principal investigator 1 | Incyte Corporation | $350.00 | 11/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612844 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8,500.00 | 11/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704119 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,929.00 | 11/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704125 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,253.55 | 11/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184261151 |
| Principal investigator 1 | Janssen Research & Development, LLC | $700.00 | 11/13/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175413718 |
| Principal investigator 1 | Incyte Corporation | $6,759.00 | 11/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611362 |
| Principal investigator 1 | Incyte Corporation | $6,759.00 | 11/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611367 |
| Principal investigator 1 | Incyte Corporation | $3,487.00 | 11/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611458 |
| Principal investigator 1 | Incyte Corporation | $1,845.00 | 11/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611706 |
| Principal investigator 1 | Incyte Corporation | $2,978.00 | 11/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611752 |
| Principal investigator 1 | Incyte Corporation | $6,278.00 | 11/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612008 |
| Principal investigator 1 | Incyte Corporation | $93.50 | 11/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612089 |
| Principal investigator 1 | Incyte Corporation | $3,687.00 | 11/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612092 |
| Principal investigator 1 | Incyte Corporation | $2,681.00 | 11/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612298 |
| Principal investigator 1 | Incyte Corporation | $2,681.00 | 11/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612303 |
| Principal investigator 1 | Incyte Corporation | $2,896.00 | 11/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612474 |
| Principal investigator 1 | Incyte Corporation | $2,896.00 | 11/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612478 |
| Principal investigator 1 | Incyte Corporation | $1,894.00 | 11/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612623 |
| Principal investigator 1 | Incyte Corporation | $2,932.00 | 11/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612645 |
| Principal investigator 1 | Incyte Corporation | $9,920.00 | 11/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612656 |
| Principal investigator 1 | Incyte Corporation | $5,349.00 | 11/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612716 |
| Principal investigator 1 | Incyte Corporation | $2,090.00 | 11/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612764 |
| Principal investigator 1 | Incyte Corporation | $3,051.00 | 11/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612768 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $416.93 | 11/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805631 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $271.91 | 11/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805633 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $265.56 | 11/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805635 |
| Principal investigator 1 | Incyte Corporation | $413.80 | 11/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240612403 |
| Principal investigator 1 | Incyte Corporation | $726.00 | 11/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240612761 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,824.00 | 11/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175413742 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,050.00 | 11/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190341618 |
| Principal investigator 1 | BioNTech SE | $211.00 | 11/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012695 |
| Principal investigator 1 | BioNTech SE | $625.00 | 11/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012699 |
| Principal investigator 1 | BioNTech SE | $135.00 | 11/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012871 |
| Principal investigator 1 | BioNTech SE | $135.00 | 11/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012873 |
| Principal investigator 1 | BioNTech SE | $1,333.00 | 11/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012875 |
| Principal investigator 1 | BioNTech SE | $115.00 | 11/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012879 |
| Principal investigator 1 | BioNTech SE | $3,038.00 | 11/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012885 |
| Principal investigator 1 | BioNTech SE | $675.00 | 11/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012899 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 11/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240611569 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 11/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612482 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 11/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1240612486 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,126.00 | 11/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175413760 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,031.00 | 11/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175414030 |
| Principal investigator 1 | ABBVIE INC. | $32,887.35 | 11/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202522739 |
| Principal investigator 1 | ABBVIE INC. | $3,866.94 | 11/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202522785 |
| Principal investigator 1 | ABBVIE INC. | $11,586.40 | 11/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202523141 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 11/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611669 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 11/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611675 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 11/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611679 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 11/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611683 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 11/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611848 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 11/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611851 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 11/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611855 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 11/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611859 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 11/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612236 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 11/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612240 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 11/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612244 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 11/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612249 |
| Principal investigator 1 | Incyte Corporation | $5,675.00 | 11/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612641 |
| Principal investigator 1 | BioNTech SE | $1,823.00 | 11/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012811 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $145.00 | 11/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704105 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7,439.00 | 11/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704121 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8,201.00 | 11/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704123 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.00 | 11/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704127 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $61.00 | 11/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704129 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $101.00 | 11/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704131 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $101.00 | 11/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704133 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 11/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611523 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 11/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611527 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 11/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611585 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 11/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611589 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 11/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611981 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 11/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611985 |
| Principal investigator 1 | Incyte Corporation | $5,675.00 | 11/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612847 |
| Principal investigator 1 | Incyte Corporation | $5,675.00 | 11/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612851 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 11/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577744 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 11/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577746 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 11/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704101 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704195 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704197 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $405.00 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704309 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,166.75 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704311 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $675.00 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704313 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $835.65 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704315 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.50 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704317 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,197.45 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704319 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $285.00 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704321 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $436.05 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704323 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $143.10 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704325 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $121.50 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704327 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $675.00 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704329 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $636.03 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704331 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $153.90 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704333 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $529.20 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704335 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $209.25 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704337 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,518.75 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704339 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704341 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,000.00 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704343 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $978.75 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704345 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7,947.20 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704347 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,216.28 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704349 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,025.00 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704351 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,594.70 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704353 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,362.31 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704355 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,145.15 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704357 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,432.56 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704359 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7,500.00 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704361 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9,750.00 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704363 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,037.50 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704365 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9,450.00 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704367 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704441 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704443 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $306,978.20 | 10/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220996756 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16,674.00 | 10/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804788 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $316.22 | 10/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805343 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $426.11 | 10/29/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804780 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $423.75 | 10/29/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804782 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $409.75 | 10/29/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804784 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $374.51 | 10/29/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804786 |
| Principal investigator 1 | Incyte Corporation | $5,675.00 | 10/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611592 |
| Principal investigator 1 | Incyte Corporation | $5,675.00 | 10/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611596 |
| Principal investigator 1 | Incyte Corporation | $5,675.00 | 10/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611599 |
| Principal investigator 1 | Incyte Corporation | $5,675.00 | 10/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611604 |
| Principal investigator 1 | Incyte Corporation | $5,675.00 | 10/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611609 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 10/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611813 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 10/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611817 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 10/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611821 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 10/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611825 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 10/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611829 |
| Principal investigator 1 | Incyte Corporation | $4,131.00 | 10/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612011 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 10/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612065 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 10/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612069 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 10/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612073 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 10/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612077 |
| Principal investigator 1 | Incyte Corporation | $3,780.00 | 10/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612081 |
| Principal investigator 1 | Incyte Corporation | $2,068.00 | 10/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612349 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 10/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612592 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 10/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612600 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 10/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612603 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 10/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612607 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 10/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612611 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,555.66 | 10/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190336051 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $158.11 | 10/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805341 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $350.27 | 10/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805629 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,801.00 | 10/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388477 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 10/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389781 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $379.00 | 10/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389787 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 10/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389793 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 10/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389799 |
| Principal investigator 1 | Incyte Corporation | $600.00 | 10/24/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611633 |
| Principal investigator 1 | Incyte Corporation | $142.95 | 10/24/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612467 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,672.00 | 10/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804951 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22,299.00 | 10/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805339 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,140.80 | 10/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805627 |
| Principal investigator 1 | ABBVIE INC. | $726.00 | 10/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202518111 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,578.00 | 10/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805337 |
| Principal investigator 1 | BeOne Medicines Ltd. | $65.00 | 10/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190329285 |
| Principal investigator 1 | BeOne Medicines Ltd. | $65.00 | 10/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190329303 |
| Principal investigator 1 | BeOne Medicines Ltd. | $98.00 | 10/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190329323 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,025.00 | 10/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334502 |
| Principal investigator 1 | BeOne Medicines Ltd. | $260.00 | 10/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334550 |
| Principal investigator 1 | BeOne Medicines Ltd. | $52.00 | 10/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334606 |
| Principal investigator 1 | BeOne Medicines Ltd. | $52.00 | 10/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334631 |
| Principal investigator 1 | BeOne Medicines Ltd. | $130.00 | 10/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334663 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,893.00 | 10/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334771 |
| Principal investigator 1 | BeOne Medicines Ltd. | $325.00 | 10/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190334775 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $419.92 | 10/19/2025 | Covered Recipient Physician | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184115627 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $419.92 | 10/19/2025 | Covered Recipient Physician | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184115629 |
| Principal investigator 1 | Genentech, Inc. | $46,781.00 | 10/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211682012 |
| Principal investigator 1 | BioNTech SE | $135.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012703 |
| Principal investigator 1 | BioNTech SE | $135.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012707 |
| Principal investigator 1 | BioNTech SE | $135.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012709 |
| Principal investigator 1 | BioNTech SE | $675.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012711 |
| Principal investigator 1 | BioNTech SE | $379.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012713 |
| Principal investigator 1 | BioNTech SE | $135.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012715 |
| Principal investigator 1 | BioNTech SE | $1,772.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012717 |
| Principal investigator 1 | BioNTech SE | $1,147.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012719 |
| Principal investigator 1 | BioNTech SE | $2,200.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012721 |
| Principal investigator 1 | BioNTech SE | $203.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012723 |
| Principal investigator 1 | BioNTech SE | $115.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012725 |
| Principal investigator 1 | BioNTech SE | $115.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012727 |
| Principal investigator 1 | BioNTech SE | $313.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012731 |
| Principal investigator 1 | BioNTech SE | $77.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012733 |
| Principal investigator 1 | BioNTech SE | $6,485.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012735 |
| Principal investigator 1 | BioNTech SE | $201.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012737 |
| Principal investigator 1 | BioNTech SE | $177.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012741 |
| Principal investigator 1 | BioNTech SE | $101.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012743 |
| Principal investigator 1 | BioNTech SE | $101.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012745 |
| Principal investigator 1 | Incyte Corporation | $3,487.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611481 |
| Principal investigator 1 | Incyte Corporation | $3,487.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611485 |
| Principal investigator 1 | Incyte Corporation | $2,090.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611488 |
| Principal investigator 1 | Incyte Corporation | $2,090.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611493 |
| Principal investigator 1 | Incyte Corporation | $2,090.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611497 |
| Principal investigator 1 | Incyte Corporation | $1,845.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611550 |
| Principal investigator 1 | Incyte Corporation | $1,845.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611554 |
| Principal investigator 1 | Incyte Corporation | $1,845.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611558 |
| Principal investigator 1 | Incyte Corporation | $3,687.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611786 |
| Principal investigator 1 | Incyte Corporation | $3,687.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611790 |
| Principal investigator 1 | Incyte Corporation | $3,051.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611863 |
| Principal investigator 1 | Incyte Corporation | $3,051.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611867 |
| Principal investigator 1 | Incyte Corporation | $3,051.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611870 |
| Principal investigator 1 | Incyte Corporation | $2,807.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611889 |
| Principal investigator 1 | Incyte Corporation | $2,807.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611893 |
| Principal investigator 1 | Incyte Corporation | $2,807.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611896 |
| Principal investigator 1 | Incyte Corporation | $2,896.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611923 |
| Principal investigator 1 | Incyte Corporation | $2,896.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611927 |
| Principal investigator 1 | Incyte Corporation | $6,278.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612159 |
| Principal investigator 1 | Incyte Corporation | $6,278.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612163 |
| Principal investigator 1 | Incyte Corporation | $6,278.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612166 |
| Principal investigator 1 | Incyte Corporation | $4,242.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612170 |
| Principal investigator 1 | Incyte Corporation | $4,242.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612174 |
| Principal investigator 1 | Incyte Corporation | $2,485.30 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612189 |
| Principal investigator 1 | Incyte Corporation | $9,920.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612194 |
| Principal investigator 1 | Incyte Corporation | $9,920.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612197 |
| Principal investigator 1 | Incyte Corporation | $9,920.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612201 |
| Principal investigator 1 | Incyte Corporation | $9,920.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612207 |
| Principal investigator 1 | Incyte Corporation | $1,894.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612253 |
| Principal investigator 1 | Incyte Corporation | $1,894.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612257 |
| Principal investigator 1 | Incyte Corporation | $1,894.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612261 |
| Principal investigator 1 | Incyte Corporation | $2,932.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612664 |
| Principal investigator 1 | Incyte Corporation | $2,932.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612669 |
| Principal investigator 1 | Incyte Corporation | $2,681.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612672 |
| Principal investigator 1 | Incyte Corporation | $2,681.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612677 |
| Principal investigator 1 | Incyte Corporation | $5,349.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612865 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,872.62 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184250537 |
| Principal investigator 1 | SEAGEN INC. | $25,341.00 | 10/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 2 MULTICOHORT OPENLABEL MULTICENTER CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DISITAMAB VEDOTIN RC48ADC ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH LOCALLYADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA THAT EXPRESSES HER2 | No dispute reported | 06/30/2026 | 1228814296 |
| Principal investigator 1 | BeOne Medicines Ltd. | $47,160.00 | 10/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336802 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.88 | 10/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388715 |
| Principal investigator 1 | Incyte Corporation | $122.00 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611519 |
| Principal investigator 1 | Incyte Corporation | $1,710.45 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611620 |
| Principal investigator 1 | Incyte Corporation | $675.00 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611636 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611649 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611653 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611656 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611662 |
| Principal investigator 1 | Incyte Corporation | $889.34 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611687 |
| Principal investigator 1 | Incyte Corporation | $5,305.00 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611749 |
| Principal investigator 1 | Incyte Corporation | $900.00 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611783 |
| Principal investigator 1 | Incyte Corporation | $589.34 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611903 |
| Principal investigator 1 | Incyte Corporation | $589.34 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611907 |
| Principal investigator 1 | Incyte Corporation | $895.15 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611941 |
| Principal investigator 1 | Incyte Corporation | $745.47 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612019 |
| Principal investigator 1 | Incyte Corporation | $234.00 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240612116 |
| Principal investigator 1 | Incyte Corporation | $234.00 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240612119 |
| Principal investigator 1 | Incyte Corporation | $61.00 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240612209 |
| Principal investigator 1 | Incyte Corporation | $1,189.34 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612268 |
| Principal investigator 1 | Incyte Corporation | $740.00 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240612281 |
| Principal investigator 1 | Incyte Corporation | $4,836.00 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240612289 |
| Principal investigator 1 | Incyte Corporation | $581.20 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612291 |
| Principal investigator 1 | Incyte Corporation | $866.10 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612526 |
| Principal investigator 1 | Incyte Corporation | $600.00 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612535 |
| Principal investigator 1 | Incyte Corporation | $1,250.00 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240612573 |
| Principal investigator 1 | Incyte Corporation | $520.00 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240612576 |
| Principal investigator 1 | Incyte Corporation | $81.42 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612705 |
| Principal investigator 1 | Incyte Corporation | $6,570.45 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240612737 |
| Principal investigator 1 | Incyte Corporation | $277.71 | 10/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612835 |
| Principal investigator 1 | ABBVIE INC. | $786.49 | 10/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202516637 |
| Principal investigator 1 | ABBVIE INC. | $1,663.00 | 10/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202516639 |
| Principal investigator 1 | ABBVIE INC. | $14,621.85 | 10/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202516641 |
| Principal investigator 1 | ABBVIE INC. | $821.00 | 10/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202516659 |
| Principal investigator 1 | ABBVIE INC. | $3,529.00 | 10/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202516671 |
| Principal investigator 1 | ABBVIE INC. | $1,345.00 | 10/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202516673 |
| Principal investigator 1 | ABBVIE INC. | $1,586.00 | 10/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202516679 |
| Principal investigator 1 | ABBVIE INC. | $884.00 | 10/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202516685 |
| Principal investigator 1 | ABBVIE INC. | $1,779.00 | 10/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202516687 |
| Principal investigator 1 | ABBVIE INC. | $2,518.00 | 10/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202516689 |
| Principal investigator 1 | ABBVIE INC. | $1,525.00 | 10/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202516697 |
| Principal investigator 1 | ABBVIE INC. | $1,410.00 | 10/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202516699 |
| Principal investigator 1 | ABBVIE INC. | $4,773.00 | 10/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202516701 |
| Principal investigator 1 | ABBVIE INC. | $1,812.00 | 10/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202516703 |
| Principal investigator 1 | ABBVIE INC. | $2,440.00 | 10/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202516705 |
| Principal investigator 1 | BeOne Medicines Ltd. | $15,927.12 | 10/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190336060 |
| Principal investigator 1 | BeOne Medicines Ltd. | $16,587.12 | 10/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190336068 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 10/13/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175413785 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 10/13/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175414011 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $317.20 | 10/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388405 |
| Principal investigator 1 | Incyte Corporation | $923.40 | 10/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612411 |
| Principal investigator 1 | ABBVIE INC. | $4,288.00 | 10/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202514261 |
| Principal investigator 1 | ABBVIE INC. | $3,149.00 | 10/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202514263 |
| Principal investigator 1 | ABBVIE INC. | $16,746.75 | 10/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202514707 |
| Principal investigator 1 | ABBVIE INC. | $2,924.00 | 10/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202514845 |
| Principal investigator 1 | ABBVIE INC. | $3,023.00 | 10/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202514847 |
| Principal investigator 1 | ABBVIE INC. | $5,029.00 | 10/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202514849 |
| Principal investigator 1 | ABBVIE INC. | $30,475.00 | 10/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan | No dispute reported | 06/30/2026 | 1202515039 |
| Principal investigator 1 | ABBVIE INC. | $917.00 | 10/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202515043 |
| Principal investigator 1 | ABBVIE INC. | $1,190.00 | 10/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202515205 |
| Principal investigator 1 | ABBVIE INC. | $5,887.00 | 10/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202515207 |
| Principal investigator 1 | ABBVIE INC. | $1,485.47 | 10/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202515209 |
| Principal investigator 1 | ABBVIE INC. | $2,603.00 | 10/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202515211 |
| Principal investigator 1 | ABBVIE INC. | $4,252.50 | 10/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202515385 |
| Principal investigator 1 | ABBVIE INC. | $25,180.88 | 10/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) | No dispute reported | 06/30/2026 | 1202515387 |
| Principal investigator 1 | ABBVIE INC. | $3,771.00 | 10/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202515613 |
| Principal investigator 1 | ABBVIE INC. | $2,317.28 | 10/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202516457 |
| Principal investigator 1 | BioNTech SE | $21,089.00 | 10/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012729 |
| Principal investigator 1 | BioNTech SE | $129.00 | 10/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012739 |
| Principal investigator 1 | ABBVIE INC. | $1,624.05 | 10/08/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202513535 |
| Principal investigator 1 | ABBVIE INC. | $4,386.00 | 10/08/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202513547 |
| Principal investigator 1 | ABBVIE INC. | $14,621.85 | 10/08/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202513553 |
| Principal investigator 1 | ABBVIE INC. | $4,658.00 | 10/08/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202513555 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,150.00 | 10/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805345 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $379.00 | 10/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389761 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 10/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389789 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,801.00 | 10/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389805 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 10/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389807 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 10/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389825 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,854.30 | 10/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805313 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,903.55 | 10/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805315 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,196.55 | 10/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805317 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,835.00 | 10/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805319 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,989.00 | 10/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805321 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $675.00 | 10/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805323 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,914.00 | 10/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805325 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $675.00 | 10/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805327 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,828.00 | 10/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805329 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,117.55 | 10/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805331 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,854.30 | 10/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805333 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,253.00 | 10/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805335 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,758.00 | 10/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175413779 |
| Principal investigator 1 | BioNTech SE | $21,189.00 | 10/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012881 |
| Principal investigator 1 | BioNTech SE | $21,089.00 | 10/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012883 |
| Principal investigator 1 | BioNTech SE | $258.00 | 10/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012895 |
| Principal investigator 1 | BioNTech SE | $258.00 | 10/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327 | No dispute reported | 06/30/2026 | 1249012897 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $25,940.00 | 10/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805773 |
| Principal investigator 1 | Genentech, Inc. | $116,719.75 | 10/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211681980 |
| Principal investigator 1 | Incyte Corporation | $2,200.00 | 10/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611989 |
| Principal investigator 1 | Incyte Corporation | $17,500.00 | 10/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612023 |
| Principal investigator 1 | Incyte Corporation | $1,250.00 | 10/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612085 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 10/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612213 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 10/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612216 |
| Principal investigator 1 | Incyte Corporation | $3,000.00 | 10/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612660 |
| Principal investigator 1 | Incyte Corporation | $2,150.00 | 10/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612700 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $71,527.56 | 10/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184244569 |
| Principal investigator 1 | ABBVIE INC. | $364.50 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202513073 |
| Principal investigator 1 | ABBVIE INC. | $364.50 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202513075 |
| Principal investigator 1 | ABBVIE INC. | $364.50 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202513087 |
| Principal investigator 1 | ABBVIE INC. | $364.50 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202513107 |
| Principal investigator 1 | ABBVIE INC. | $364.50 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202513109 |
| Principal investigator 1 | ABBVIE INC. | $364.50 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202513111 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $491.40 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804768 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $885.70 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804770 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $414.45 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804772 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $356.40 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804774 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $337.50 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804776 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,248.50 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804778 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,727.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388397 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $103.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388399 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $405.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388401 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,046.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388403 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388407 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $675.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388409 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,250.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388411 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $675.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388415 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388417 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,801.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388419 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $42.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388421 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388423 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $80.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388425 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,050.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388427 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,083.99 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388429 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $185.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388433 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,668.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388437 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $105.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388439 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388441 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,920.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388443 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $205.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388445 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $78.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388447 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $641.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388449 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $743.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388455 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388457 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388461 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388465 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $58.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388467 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,000.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388471 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388473 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388475 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $84.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388485 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388487 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,750.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388489 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $72.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388491 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $113.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388495 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388497 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388645 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $236.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388647 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $69.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388649 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388651 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $69.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388653 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $113.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388655 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $270.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388657 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388659 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $105.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388661 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388663 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $574.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388665 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $58.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388667 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388669 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $42.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388671 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388673 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $69.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388675 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388677 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $198.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388679 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388681 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388683 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $42.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388685 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $84.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388687 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $205.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388689 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $69.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388691 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $169.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388693 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $42.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388695 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388697 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388699 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $405.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388701 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $185.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388703 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $108.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388705 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $103.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388707 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388709 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388711 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $203.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388713 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $263.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388717 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388719 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $80.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388721 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $72.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388723 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $810.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388725 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $100.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388727 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $506.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388729 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388731 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388733 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388735 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $58.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388737 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $143.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388739 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388741 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $42.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388743 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $57.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388745 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $100.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388747 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388749 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $624.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388751 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388753 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,817.50 | 10/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389769 |
| Principal investigator 1 | Incyte Corporation | $191.00 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611477 |
| Principal investigator 1 | Incyte Corporation | $263.00 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611546 |
| Principal investigator 1 | Incyte Corporation | $61.00 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611573 |
| Principal investigator 1 | Incyte Corporation | $61.00 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611577 |
| Principal investigator 1 | Incyte Corporation | $32.00 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611694 |
| Principal investigator 1 | Incyte Corporation | $32.00 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611698 |
| Principal investigator 1 | Incyte Corporation | $32.00 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611702 |
| Principal investigator 1 | Incyte Corporation | $130.00 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611969 |
| Principal investigator 1 | Incyte Corporation | $128.00 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611972 |
| Principal investigator 1 | Incyte Corporation | $74.00 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240612307 |
| Principal investigator 1 | Incyte Corporation | $74.00 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240612311 |
| Principal investigator 1 | Incyte Corporation | $74.00 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240612314 |
| Principal investigator 1 | Incyte Corporation | $1,930.00 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612530 |
| Principal investigator 1 | Incyte Corporation | $978.00 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612538 |
| Principal investigator 1 | Incyte Corporation | $264.21 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240612615 |
| Principal investigator 1 | Incyte Corporation | $468.00 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240612872 |
| Principal investigator 1 | Incyte Corporation | $310.00 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240612877 |
| Principal investigator 1 | Incyte Corporation | $310.00 | 10/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240612883 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 10/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577736 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 10/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577738 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $107.76 | 10/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577740 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $41.95 | 10/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577742 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 10/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704099 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704189 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704191 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 10/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704193 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,371.00 | 10/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805311 |
| Principal investigator 1 | BeOne Medicines Ltd. | $10,716.00 | 09/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190331735 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,142.50 | 09/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704307 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 09/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704431 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 09/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704433 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $450,234.69 | 09/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220996758 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $8,126.52 | 09/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220996864 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $35,108.79 | 09/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220996866 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $60,947.00 | 09/29/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804766 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,854.30 | 09/29/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805309 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,334.00 | 09/29/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805771 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $184,128.00 | 09/29/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388387 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,205.00 | 09/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804736 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,604.95 | 09/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804738 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,003.85 | 09/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804740 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,436.20 | 09/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804742 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,809.45 | 09/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804744 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,240.10 | 09/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804746 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,801.35 | 09/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804748 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,432.45 | 09/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804750 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,126.35 | 09/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804752 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,801.35 | 09/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804754 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,611.35 | 09/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804756 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,107.45 | 09/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804758 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,635.35 | 09/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804760 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,611.35 | 09/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804762 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $826.35 | 09/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804764 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 09/26/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413713 |
| Principal investigator 1 | BioNTech SE | $2,430.00 | 09/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013001 |
| Principal investigator 1 | BioNTech SE | $4,213.00 | 09/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013003 |
| Principal investigator 1 | BioNTech SE | $2,849.00 | 09/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013005 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,425.00 | 09/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804949 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $30,963.00 | 09/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805307 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $472.50 | 09/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805623 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $101,583.90 | 09/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805625 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $276.97 | 09/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805739 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $286.97 | 09/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805741 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $150.00 | 09/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805743 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $336.79 | 09/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805745 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $150.00 | 09/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805747 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $336.98 | 09/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805749 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,036.00 | 09/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805751 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $150.00 | 09/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805753 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,635.70 | 09/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805755 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,822.50 | 09/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805757 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,635.70 | 09/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805759 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,118.70 | 09/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805761 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,980.70 | 09/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805763 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $952.20 | 09/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805765 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,879.40 | 09/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805767 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,038.42 | 09/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805769 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $291.50 | 09/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220996772 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $459.54 | 09/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220996774 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $693.50 | 09/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220996776 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $916.05 | 09/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220996778 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $121.50 | 09/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220996780 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,317.88 | 09/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220996782 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $689.00 | 09/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220996784 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,253.00 | 09/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805295 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,502.00 | 09/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805297 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,253.00 | 09/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805299 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,485.00 | 09/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805301 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,914.00 | 09/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805303 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,253.00 | 09/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805305 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $3,000.00 | 09/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190331959 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $1,600.00 | 09/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190331961 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $4,250.00 | 09/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190331963 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $500.00 | 09/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190331965 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $356.79 | 09/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805737 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,637.06 | 09/23/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184241946 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $19,819.35 | 09/23/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184241948 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $19,819.35 | 09/23/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184241950 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,075.00 | 09/23/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184241952 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,075.00 | 09/23/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184241954 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $150.00 | 09/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805735 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $32.00 | 09/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389687 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,013.00 | 09/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389689 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 09/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389691 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,801.00 | 09/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389693 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $379.00 | 09/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389695 |
| Principal investigator 1 | Genentech, Inc. | $1,613.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211682002 |
| Principal investigator 1 | Incyte Corporation | $1,894.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611005 |
| Principal investigator 1 | Incyte Corporation | $2,932.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611008 |
| Principal investigator 1 | Incyte Corporation | $61.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611046 |
| Principal investigator 1 | Incyte Corporation | $230.85 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611050 |
| Principal investigator 1 | Incyte Corporation | $211.95 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611054 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611073 |
| Principal investigator 1 | Incyte Corporation | $74.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611077 |
| Principal investigator 1 | Incyte Corporation | $32.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611081 |
| Principal investigator 1 | Incyte Corporation | $196.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611086 |
| Principal investigator 1 | Incyte Corporation | $3,051.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611174 |
| Principal investigator 1 | Incyte Corporation | $3,687.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611178 |
| Principal investigator 1 | Incyte Corporation | $3,487.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611182 |
| Principal investigator 1 | Incyte Corporation | $2,090.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611186 |
| Principal investigator 1 | Incyte Corporation | $2,896.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611190 |
| Principal investigator 1 | Incyte Corporation | $1,894.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611194 |
| Principal investigator 1 | Incyte Corporation | $1,845.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611200 |
| Principal investigator 1 | Incyte Corporation | $3,051.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611204 |
| Principal investigator 1 | Incyte Corporation | $3,687.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611208 |
| Principal investigator 1 | Incyte Corporation | $3,487.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611212 |
| Principal investigator 1 | Incyte Corporation | $2,090.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611216 |
| Principal investigator 1 | Incyte Corporation | $2,896.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611220 |
| Principal investigator 1 | Incyte Corporation | $2,932.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611225 |
| Principal investigator 1 | Incyte Corporation | $1,894.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611229 |
| Principal investigator 1 | Incyte Corporation | $1,845.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611234 |
| Principal investigator 1 | Incyte Corporation | $3,687.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611238 |
| Principal investigator 1 | Incyte Corporation | $3,687.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611242 |
| Principal investigator 1 | Incyte Corporation | $2,090.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611246 |
| Principal investigator 1 | Incyte Corporation | $2,896.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611250 |
| Principal investigator 1 | Incyte Corporation | $1,894.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611254 |
| Principal investigator 1 | Incyte Corporation | $1,845.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611257 |
| Principal investigator 1 | Incyte Corporation | $2,896.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611262 |
| Principal investigator 1 | Incyte Corporation | $9,920.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611266 |
| Principal investigator 1 | Incyte Corporation | $6,278.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611276 |
| Principal investigator 1 | Incyte Corporation | $6,278.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611280 |
| Principal investigator 1 | Incyte Corporation | $101.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611291 |
| Principal investigator 1 | Incyte Corporation | $3,051.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611299 |
| Principal investigator 1 | Incyte Corporation | $3,051.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611303 |
| Principal investigator 1 | Incyte Corporation | $3,051.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611308 |
| Principal investigator 1 | Incyte Corporation | $61.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611316 |
| Principal investigator 1 | Incyte Corporation | $2,896.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611323 |
| Principal investigator 1 | Incyte Corporation | $539.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611330 |
| Principal investigator 1 | Incyte Corporation | $2,697.90 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611335 |
| Principal investigator 1 | Incyte Corporation | $9,920.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611339 |
| Principal investigator 1 | Incyte Corporation | $9,920.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611343 |
| Principal investigator 1 | Incyte Corporation | $9,920.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611347 |
| Principal investigator 1 | Incyte Corporation | $1,894.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611351 |
| Principal investigator 1 | Incyte Corporation | $1,845.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611355 |
| Principal investigator 1 | Incyte Corporation | $1,845.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1240611358 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,396.49 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413660 |
| Principal investigator 1 | Janssen Research & Development, LLC | $350.00 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413685 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,228.41 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413703 |
| Principal investigator 1 | Janssen Research & Development, LLC | $739.32 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413707 |
| Principal investigator 1 | Janssen Research & Development, LLC | $291.58 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413821 |
| Principal investigator 1 | Janssen Research & Development, LLC | $379.72 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413828 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,263.07 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413892 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,061.75 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413928 |
| Principal investigator 1 | Janssen Research & Development, LLC | $404.89 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413953 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,406.81 | 09/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413966 |
| Principal investigator 1 | BeOne Medicines Ltd. | $78,600.00 | 09/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336886 |
| Principal investigator 1 | BeOne Medicines Ltd. | $15,720.00 | 09/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336891 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,678.00 | 09/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175414002 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $9,560.00 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | BelieveIT-201 | No dispute reported | 06/30/2026 | 1233997103 |
| Principal investigator 1 | BioNTech SE | $906.00 | 09/18/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-01 | No dispute reported | 06/30/2026 | 1249012833 |
| Principal investigator 1 | BioNTech SE | $919.28 | 09/18/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-01 | No dispute reported | 06/30/2026 | 1249012839 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,439.00 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805285 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,985.99 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805573 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,985.99 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805575 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,682.25 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805577 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,611.25 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805579 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,523.53 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805581 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,282.50 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805583 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $675.00 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805585 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,926.79 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805587 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $661.50 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805589 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,985.99 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805591 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,985.99 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805593 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,496.50 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805595 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,196.79 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805597 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,021.44 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805599 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,397.29 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805601 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,196.79 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805603 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,910.25 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805605 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $601.13 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805607 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,196.79 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805609 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $114.75 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805611 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,350.28 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805613 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,112.75 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805615 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,700.00 | 09/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805617 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,860.00 | 09/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190331797 |
| Principal investigator 1 | BeOne Medicines Ltd. | $4,364.00 | 09/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190331799 |
| Principal investigator 1 | BeOne Medicines Ltd. | $4,364.00 | 09/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190331829 |
| Principal investigator 1 | BeOne Medicines Ltd. | $130.00 | 09/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190343128 |
| Principal investigator 1 | BeOne Medicines Ltd. | $130.00 | 09/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190343168 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,549.00 | 09/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190343234 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,914.00 | 09/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805279 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,914.00 | 09/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805281 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,397.40 | 09/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805283 |
| Principal investigator 1 | Incyte Corporation | $4,836.00 | 09/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611097 |
| Principal investigator 1 | Incyte Corporation | $2,068.00 | 09/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611101 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 09/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611116 |
| Principal investigator 1 | Incyte Corporation | $32.00 | 09/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611120 |
| Principal investigator 1 | Incyte Corporation | $263.00 | 09/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611123 |
| Principal investigator 1 | Incyte Corporation | $4,836.00 | 09/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611127 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 09/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611131 |
| Principal investigator 1 | Incyte Corporation | $2,068.00 | 09/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611134 |
| Principal investigator 1 | Incyte Corporation | $61.00 | 09/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611138 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 09/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611141 |
| Principal investigator 1 | Incyte Corporation | $4,836.00 | 09/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611145 |
| Principal investigator 1 | Incyte Corporation | $2,068.00 | 09/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611157 |
| Principal investigator 1 | Incyte Corporation | $9,672.00 | 09/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611160 |
| Principal investigator 1 | Incyte Corporation | $234.00 | 09/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611163 |
| Principal investigator 1 | Incyte Corporation | $2,822.00 | 09/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611284 |
| Principal investigator 1 | Incyte Corporation | $2,822.00 | 09/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611288 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 09/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611320 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,152.70 | 09/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804608 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,728.00 | 09/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804610 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,275.55 | 09/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804612 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,530.00 | 09/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804614 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,611.35 | 09/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804616 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,503.35 | 09/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804618 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,801.35 | 09/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804620 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,988.00 | 09/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804622 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,233.35 | 09/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804624 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,253.95 | 09/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804626 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,091.29 | 09/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805531 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $263.25 | 09/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805533 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,926.80 | 09/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805535 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,555.55 | 09/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805537 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,045.25 | 09/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805539 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,880.55 | 09/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805541 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,880.55 | 09/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805543 |
| Principal investigator 1 | BeOne Medicines Ltd. | $940.44 | 09/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190327589 |
| Principal investigator 1 | BioNTech SE | $77.00 | 09/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013047 |
| Principal investigator 1 | BioNTech SE | $405.00 | 09/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013049 |
| Principal investigator 1 | Janssen Research & Development, LLC | $147,277.00 | 09/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413881 |
| Principal investigator 1 | BioNTech SE | $2,025.00 | 09/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012765 |
| Principal investigator 1 | BioNTech SE | $2,700.00 | 09/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013029 |
| Principal investigator 1 | BioNTech SE | $4,000.00 | 09/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013031 |
| Principal investigator 1 | BioNTech SE | $489.00 | 09/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013033 |
| Principal investigator 1 | BioNTech SE | $1,620.00 | 09/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013035 |
| Principal investigator 1 | BioNTech SE | $2,025.00 | 09/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013037 |
| Principal investigator 1 | BioNTech SE | $1,267.00 | 09/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013039 |
| Principal investigator 1 | BioNTech SE | $3,000.00 | 09/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013041 |
| Principal investigator 1 | BioNTech SE | $1,505.00 | 09/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013043 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,914.00 | 09/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805287 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,237.00 | 09/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805289 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,914.00 | 09/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805291 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,633.00 | 09/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805293 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $78.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388307 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $270.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388313 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,801.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388315 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $405.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388317 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $42.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388319 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388321 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $103.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388323 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $641.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388325 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388327 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $113.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388353 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $80.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388357 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $84.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388359 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $72.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388361 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388363 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $472.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388365 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388367 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $34.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388369 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $641.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388371 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $675.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388373 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $58.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388375 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388377 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $675.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388379 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $105.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388389 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $205.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388393 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 09/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388395 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804724 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804726 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804728 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804730 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,744.75 | 09/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804732 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805619 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805621 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805501 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805503 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805505 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805507 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805509 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,056.25 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804917 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,056.25 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804919 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,056.25 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804921 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22,891.95 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804923 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,316.00 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804925 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,716.20 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804927 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,982.25 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804929 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $40.43 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804931 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,880.25 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804933 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,565.05 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804935 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,127.95 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804937 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $189.00 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804939 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,991.40 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804941 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $243.50 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804943 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,008.15 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804945 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $611.55 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388329 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388331 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,456.00 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388333 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388335 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,817.50 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388337 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,251.00 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388339 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388341 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $379.00 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388343 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,122.00 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388345 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $270.00 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388347 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $675.00 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388349 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $675.00 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388351 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,200.00 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388381 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388383 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,375.00 | 09/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388385 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19,378.55 | 09/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805257 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $750.00 | 09/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805259 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,750.00 | 09/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805261 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $150.00 | 09/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805263 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,150.00 | 09/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805265 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,557.00 | 09/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805267 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,900.00 | 09/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805269 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17,064.00 | 09/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805271 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,050.00 | 09/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805273 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $68.00 | 09/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805275 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $168.00 | 09/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805277 |
| Principal investigator 1 | Incyte Corporation | $1,750.00 | 09/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611031 |
| Principal investigator 1 | Incyte Corporation | $3,300.00 | 09/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611035 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 09/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611043 |
| Principal investigator 1 | Incyte Corporation | $4,000.00 | 09/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611057 |
| Principal investigator 1 | ABBVIE INC. | $7,965.00 | 09/04/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202508846 |
| Principal investigator 1 | ABBVIE INC. | $35,511.08 | 09/04/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) | No dispute reported | 06/30/2026 | 1202508848 |
| Principal investigator 1 | ABBVIE INC. | $8,049.98 | 09/04/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202508934 |
| Principal investigator 1 | ABBVIE INC. | $15,313.05 | 09/04/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202508936 |
| Principal investigator 1 | BioNTech SE | $21,089.00 | 09/04/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012859 |
| Principal investigator 1 | BioNTech SE | $21,089.00 | 09/04/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012861 |
| Principal investigator 1 | BioNTech SE | $21,089.00 | 09/04/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012965 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804632 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804634 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804636 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804638 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,284.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804640 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804642 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804644 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804646 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804648 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804650 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,240.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804652 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804654 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804656 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,164.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804658 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,164.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804660 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,164.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804662 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,548.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804664 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,548.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804666 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,548.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804668 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,548.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804670 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,548.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804672 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,240.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804674 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,548.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804676 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,284.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804678 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,240.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804680 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,284.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804682 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,548.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804684 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,548.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804686 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,164.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804688 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,548.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804690 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804692 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804694 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804696 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804698 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804700 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804702 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804704 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,284.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804706 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,240.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804708 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,284.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804710 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,548.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804712 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,164.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804714 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,284.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804716 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,548.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804718 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,240.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804720 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,240.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804722 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,056.25 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804947 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19,941.52 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805563 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19,334.03 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805565 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $341.60 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805567 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $324.20 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805569 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $405.52 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805571 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,334.00 | 09/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805733 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,661.42 | 09/04/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184235401 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $355.00 | 09/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704079 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9,945.00 | 09/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704081 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9,694.00 | 09/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704083 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,346.00 | 09/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704085 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $790.00 | 09/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704087 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $145.00 | 09/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704089 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.00 | 09/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704091 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,986.00 | 09/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704093 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,986.00 | 09/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704095 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $355.00 | 09/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704097 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,709.55 | 09/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804734 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $97.00 | 09/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389707 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 09/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389709 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,075.00 | 09/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389749 |
| Principal investigator 1 | Incyte Corporation | $6,000.00 | 09/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611039 |
| Principal investigator 1 | Incyte Corporation | $176.89 | 09/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611269 |
| Principal investigator 1 | BeOne Medicines Ltd. | $3,440.00 | 09/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190331733 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577732 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577734 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704039 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704185 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704187 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $597,154.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804606 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $810.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805159 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $810.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805161 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $810.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805163 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,945.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805165 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,633.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805167 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,049.94 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805169 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,224.50 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805171 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $100.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805173 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $494.05 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805175 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $415.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805177 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,092.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805179 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,018.75 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805181 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $640.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805183 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $673.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805185 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,498.30 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805187 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,016.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805189 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,143.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805191 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,818.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805193 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $121.70 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805195 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $136.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805197 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,007.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805199 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $336.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805201 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,301.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805203 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,801.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805205 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $283.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805207 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,521.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805209 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,307.75 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805211 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,375.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805213 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $824.53 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805483 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,724.38 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805485 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,852.03 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805487 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $845.53 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805489 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,004.15 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805491 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,844.53 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805493 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,683.28 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805495 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,270.03 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805497 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,640.78 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805499 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $45,724.00 | 09/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805731 |
| Principal investigator 1 | Janssen Research & Development, LLC | $55,701.00 | 09/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413667 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,250.00 | 08/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704303 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $734.05 | 08/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704305 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 08/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704445 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 08/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704447 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,358.00 | 08/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220804813 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24,522.00 | 08/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804915 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $55,373.00 | 08/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805231 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $52,953.30 | 08/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805481 |
| Principal investigator 1 | BeOne Medicines Ltd. | $32,322.30 | 08/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190344615 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $93.28 | 08/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704435 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 08/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704437 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.00 | 08/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704439 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $8,859.59 | 08/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220996844 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $863.23 | 08/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220996846 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $5,754.14 | 08/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220996848 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $339.40 | 08/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220996874 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $199.80 | 08/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220996876 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $14.60 | 08/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220996878 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $702.77 | 08/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805227 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $115.09 | 08/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805229 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,100.66 | 08/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805475 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $754.65 | 08/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805477 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,827.00 | 08/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805479 |
| Principal investigator 1 | Genentech, Inc. | $1,913.00 | 08/26/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211681982 |
| Principal investigator 1 | Genentech, Inc. | $19,098.89 | 08/26/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211682008 |
| Principal investigator 1 | Genentech, Inc. | $29,440.55 | 08/26/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211682010 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,709.55 | 08/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804630 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $100.00 | 08/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805235 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,768.30 | 08/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805237 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,241.85 | 08/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805239 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $120.00 | 08/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805241 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,548.00 | 08/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805243 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 08/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805245 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,498.30 | 08/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805247 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,498.30 | 08/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805249 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $675.00 | 08/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805251 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,179.30 | 08/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805253 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $162.82 | 08/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805255 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $74.50 | 08/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388309 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $119.20 | 08/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388311 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $74.50 | 08/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388355 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $74.50 | 08/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388391 |
| Principal investigator 1 | Genentech, Inc. | $263.00 | 08/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211681984 |
| Principal investigator 1 | Genentech, Inc. | $340.00 | 08/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211681986 |
| Principal investigator 1 | Genentech, Inc. | $1,675.00 | 08/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211681988 |
| Principal investigator 1 | Genentech, Inc. | $571.00 | 08/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211681990 |
| Principal investigator 1 | Genentech, Inc. | $1,913.00 | 08/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211681992 |
| Principal investigator 1 | Genentech, Inc. | $348.00 | 08/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211681994 |
| Principal investigator 1 | Genentech, Inc. | $409.00 | 08/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211681996 |
| Principal investigator 1 | Genentech, Inc. | $340.00 | 08/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211681998 |
| Principal investigator 1 | Genentech, Inc. | $2,548.00 | 08/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211682000 |
| Principal investigator 1 | Genentech, Inc. | $2,429.00 | 08/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211682004 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,540.00 | 08/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413809 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 08/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413904 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,950.00 | 08/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413943 |
| Principal investigator 1 | Janssen Research & Development, LLC | $27,636.00 | 08/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413986 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,709.55 | 08/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804628 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $369.90 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805435 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,116.25 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805437 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $780.42 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805439 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,049.75 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805441 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,085.28 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805443 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,170.78 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805445 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,580.48 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805447 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,447.43 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805449 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,997.78 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805451 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,985.85 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805453 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,045.25 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805455 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,323.35 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805457 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,625.75 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805459 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,120.85 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805461 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,523.03 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805463 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,247.90 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805465 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,099.25 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805467 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $546.10 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805469 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,997.89 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805471 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389605 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389633 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $32.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389635 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389637 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,013.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389639 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389641 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $54.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389643 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $32.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389645 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $61.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389647 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,013.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389649 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $32.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389651 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $205.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389653 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389655 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389657 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,013.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389659 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $205.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389661 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $32.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389663 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $32.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389697 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389699 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,013.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389701 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389703 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389705 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $32.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389711 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389713 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $32.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389715 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,801.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389717 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389719 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,013.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389721 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,013.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389723 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389739 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389741 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $624.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389745 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $32.00 | 08/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389753 |
| Principal investigator 1 | BioNTech SE | $27,029.00 | 08/21/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012967 |
| Principal investigator 1 | BioNTech SE | $7,560.00 | 08/21/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012973 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,007.45 | 08/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804594 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $749.30 | 08/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804596 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17,093.70 | 08/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804598 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 08/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804600 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,384.15 | 08/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804602 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17,093.70 | 08/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804604 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,752.54 | 08/21/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184229905 |
| Principal investigator 1 | BeOne Medicines Ltd. | $31,440.00 | 08/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190342203 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $413.75 | 08/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805157 |
| Principal investigator 1 | Genentech, Inc. | $19,800.00 | 08/20/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL | No dispute reported | 06/30/2026 | 1211681954 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,506.00 | 08/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805155 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 08/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805215 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19,063.00 | 08/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805217 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,810.00 | 08/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805219 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,146.50 | 08/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805221 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,658.45 | 08/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805223 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,772.14 | 08/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805225 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,269.40 | 08/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805473 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,103.00 | 08/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804909 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,389.00 | 08/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804911 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $817.00 | 08/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804913 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,002.00 | 08/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804907 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,637.06 | 08/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184228593 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,298.00 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805103 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805105 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805107 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805109 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805111 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805113 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805115 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805117 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805119 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805121 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805123 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805125 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805127 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805129 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805131 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805133 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,205.35 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805135 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,565.80 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805137 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,722.40 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805139 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,498.30 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805141 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,651.80 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805143 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805145 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,205.35 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805147 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,565.80 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805149 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,610.35 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805151 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,498.30 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805153 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,801.00 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389615 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,013.00 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389617 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,075.00 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389619 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389725 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389727 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $675.00 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389729 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 08/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389755 |
| Principal investigator 1 | Incyte Corporation | $440.00 | 08/13/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611148 |
| Principal investigator 1 | Incyte Corporation | $240.00 | 08/13/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611153 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 08/13/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611167 |
| Principal investigator 1 | Incyte Corporation | $2,780.00 | 08/13/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611171 |
| Principal investigator 1 | Incyte Corporation | $1,400.00 | 08/13/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611272 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $10,631.51 | 08/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220996838 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $863.23 | 08/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220996840 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $5,754.14 | 08/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220996842 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 08/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389609 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 08/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389611 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 08/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389613 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $31,189.33 | 08/08/2025 | Non-covered Recipient Entity Valkyrie Global, Inc | A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235992019 |
| Principal investigator 1 | Genentech, Inc. | $1,419.00 | 08/08/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211682006 |
| Principal investigator 1 | BioNTech SE | $3,780.00 | 08/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012971 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,577.00 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220804815 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $29,000.00 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220804817 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,410.25 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805233 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,750.00 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805545 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $779.89 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805547 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22,763.03 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805549 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,894.87 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805551 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $622.50 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805553 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,892.85 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805555 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $568.43 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805557 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $622.50 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805559 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $422.12 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805561 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,240.00 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388573 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,500.00 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388613 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,668.00 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388615 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,375.00 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388617 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,050.00 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388619 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,000.00 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388621 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $743.00 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388623 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,920.00 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388625 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,750.00 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388627 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,750.00 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388629 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388631 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $205.00 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389671 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $32.00 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389673 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.00 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389675 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $462.00 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389677 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $100.00 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389679 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $61.00 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389681 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389683 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $57.00 | 08/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389743 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $19,202.00 | 08/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184226503 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $19,819.35 | 08/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184226505 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $273.90 | 08/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184226507 |
| Principal investigator 1 | ABBVIE INC. | $50,336.10 | 08/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202502608 |
| Principal investigator 1 | ABBVIE INC. | $56,655.48 | 08/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) | No dispute reported | 06/30/2026 | 1202502610 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $203.00 | 08/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704043 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,487.00 | 08/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704045 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $829.00 | 08/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704047 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $236.00 | 08/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704049 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $101.00 | 08/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704051 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $236.00 | 08/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704053 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $675.00 | 08/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704055 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $101.00 | 08/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704057 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $155.00 | 08/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704059 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $42.00 | 08/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704061 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.00 | 08/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704063 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $105.00 | 08/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704065 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $68.00 | 08/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704067 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $105.00 | 08/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704069 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $567.68 | 08/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704071 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $68.00 | 08/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704075 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $155.00 | 08/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704077 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 08/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389665 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 08/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389667 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 08/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389669 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,143.00 | 08/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389747 |
| Principal investigator 1 | Incyte Corporation | $5,250.00 | 08/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611012 |
| Principal investigator 1 | Incyte Corporation | $1,250.00 | 08/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611016 |
| Principal investigator 1 | Incyte Corporation | $4,842.00 | 08/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611021 |
| Principal investigator 1 | Incyte Corporation | $307.90 | 08/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611023 |
| Principal investigator 1 | Incyte Corporation | $1,750.00 | 08/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611027 |
| Principal investigator 1 | Incyte Corporation | $3,475.00 | 08/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611295 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 08/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611313 |
| Principal investigator 1 | BeOne Medicines Ltd. | $12,114.12 | 08/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190344541 |
| Principal investigator 1 | BeOne Medicines Ltd. | $257.00 | 08/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190344603 |
| Principal investigator 1 | BeOne Medicines Ltd. | $660.00 | 08/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190344607 |
| Principal investigator 1 | BeOne Medicines Ltd. | $660.00 | 08/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190344611 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $190.79 | 08/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804588 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,106.35 | 08/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804590 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $582.02 | 08/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804592 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,075.00 | 08/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805511 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,750.00 | 08/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805513 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,750.00 | 08/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805515 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,750.00 | 08/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805517 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,376.47 | 08/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805519 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,376.48 | 08/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805521 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,593.91 | 08/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805523 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,376.48 | 08/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805525 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19,941.53 | 08/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805527 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19,941.53 | 08/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805529 |
| Principal investigator 1 | BioNTech SE | $1,890.00 | 08/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013007 |
| Principal investigator 1 | BioNTech SE | $4,532.00 | 08/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013051 |
| Principal investigator 1 | BioNTech SE | $3,686.00 | 08/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013053 |
| Principal investigator 1 | BioNTech SE | $4,018.00 | 08/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013055 |
| Principal investigator 1 | BioNTech SE | $4,030.00 | 08/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013057 |
| Principal investigator 1 | BioNTech SE | $129.00 | 08/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013059 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577728 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577730 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704037 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $145.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704073 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704181 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704183 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $80.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388499 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $257.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388501 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $169.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388503 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $103.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388505 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $57.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388519 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $105.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388521 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388523 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $100.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388525 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388527 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $405.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388529 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $42.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388531 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $72.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388533 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $203.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388535 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $540.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388537 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $84.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388539 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $58.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388541 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $675.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388543 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388545 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388547 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388549 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388551 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $113.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388553 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $58.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388555 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388557 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388633 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $205.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388637 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $379.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388641 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15,000.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389631 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,127.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389735 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,750.00 | 08/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389737 |
| Principal investigator 1 | ABBVIE INC. | $26,611.20 | 07/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202500640 |
| Principal investigator 1 | BioNTech SE | $135.00 | 07/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012845 |
| Principal investigator 1 | BioNTech SE | $135.00 | 07/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012847 |
| Principal investigator 1 | BioNTech SE | $135.00 | 07/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012849 |
| Principal investigator 1 | BioNTech SE | $135.00 | 07/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012851 |
| Principal investigator 1 | BioNTech SE | $115.00 | 07/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012853 |
| Principal investigator 1 | BioNTech SE | $115.00 | 07/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012855 |
| Principal investigator 1 | BioNTech SE | $115.00 | 07/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012857 |
| Principal investigator 1 | BioNTech SE | $203.00 | 07/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012863 |
| Principal investigator 1 | BioNTech SE | $405.00 | 07/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012865 |
| Principal investigator 1 | BioNTech SE | $135.00 | 07/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012951 |
| Principal investigator 1 | BioNTech SE | $182.00 | 07/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012953 |
| Principal investigator 1 | BioNTech SE | $270.00 | 07/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012955 |
| Principal investigator 1 | BioNTech SE | $3,176.00 | 07/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012957 |
| Principal investigator 1 | BioNTech SE | $149.00 | 07/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012959 |
| Principal investigator 1 | BioNTech SE | $380.00 | 07/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012961 |
| Principal investigator 1 | BioNTech SE | $115.00 | 07/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012963 |
| Principal investigator 1 | BioNTech SE | $254.00 | 07/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012969 |
| Principal investigator 1 | BioNTech SE | $203.00 | 07/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012975 |
| Principal investigator 1 | BioNTech SE | $405.00 | 07/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012977 |
| Principal investigator 1 | BioNTech SE | $101.00 | 07/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012979 |
| Principal investigator 1 | BioNTech SE | $47.00 | 07/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012981 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25,062.53 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704259 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $27,490.66 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704261 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $27,923.50 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704263 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $26,492.18 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704265 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24,992.95 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704267 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $26,107.73 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704269 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $32,844.87 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704271 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25,595.00 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704273 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $18,427.50 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704275 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $147,608.34 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704277 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20,250.00 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704279 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13,821.30 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704281 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20,250.00 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704283 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20,250.00 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704285 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16,726.50 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704287 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20,250.00 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704289 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20,250.00 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704291 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20,250.00 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704293 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20,250.00 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704295 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16,368.75 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704297 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20,250.00 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704299 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13,213.80 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704301 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704423 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704425 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $82.10 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704427 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.92 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704429 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $753.26 | 07/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804586 |
| Principal investigator 1 | AstraZeneca UK Limited | $157,266.75 | 07/30/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | a phase 2,open label study to evaluate the safety,tolerability,pharmacokinetics,immunogenicity,and antitumor activity of volrustomig priming regimen in combination with other anticancer agents in participants with solid tumors evolve 01 | No dispute reported | 06/30/2026 | 1185552417 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $314.09 | 07/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805097 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $238.05 | 07/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805099 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $317.08 | 07/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805101 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $523.00 | 07/29/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190331957 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $377.39 | 07/29/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804903 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,850.48 | 07/29/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804905 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,179.30 | 07/29/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805095 |
| Principal investigator 1 | Genentech, Inc. | $15,470.00 | 07/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL | No dispute reported | 06/30/2026 | 1211681950 |
| Principal investigator 1 | Genentech, Inc. | $20,184.00 | 07/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL | No dispute reported | 06/30/2026 | 1211681952 |
| Principal investigator 1 | Genentech, Inc. | $39,769.00 | 07/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211681972 |
| Principal investigator 1 | BioNTech SE | $4,532.00 | 07/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013009 |
| Principal investigator 1 | BioNTech SE | $4,018.00 | 07/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013011 |
| Principal investigator 1 | BioNTech SE | $4,030.00 | 07/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013013 |
| Principal investigator 1 | BioNTech SE | $129.00 | 07/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013015 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $509.10 | 07/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220996868 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $299.70 | 07/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220996870 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $21.90 | 07/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220996872 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,981.95 | 07/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805065 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $70.00 | 07/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805067 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,069.10 | 07/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805069 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $488.50 | 07/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805071 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $120.00 | 07/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805073 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $170.00 | 07/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805075 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 07/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805077 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $100.00 | 07/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805079 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,082.85 | 07/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805081 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.00 | 07/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805083 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $70.00 | 07/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805085 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,981.95 | 07/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805087 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,019.10 | 07/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805089 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,179.30 | 07/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805091 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,179.30 | 07/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805093 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,993.00 | 07/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805729 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 07/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413655 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,101.16 | 07/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805063 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 07/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388579 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $213.00 | 07/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388581 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $100.00 | 07/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388583 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 07/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388585 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $198.00 | 07/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388587 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.00 | 07/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388589 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $57.00 | 07/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388591 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.00 | 07/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388593 |
| Principal investigator 1 | ABBVIE INC. | $14,623.00 | 07/24/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202499634 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $710.20 | 07/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804582 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,968.74 | 07/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804584 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $421.76 | 07/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805047 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $35.59 | 07/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805049 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $402.65 | 07/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805051 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $239.68 | 07/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805053 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $202.82 | 07/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805055 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $259.26 | 07/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805057 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,810.00 | 07/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805059 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $581.73 | 07/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805061 |
| Principal investigator 1 | PFIZER INC. | $2,257.20 | 07/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228715241 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,391.00 | 07/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190327591 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,863.00 | 07/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190327593 |
| Principal investigator 1 | BeOne Medicines Ltd. | $11,181.00 | 07/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190331739 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,482.00 | 07/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190344592 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,906.00 | 07/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190344598 |
| Principal investigator 1 | BeOne Medicines Ltd. | $11,201.62 | 07/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190344622 |
| Principal investigator 1 | BeOne Medicines Ltd. | $1,326.00 | 07/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190344627 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,892.95 | 07/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804901 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,498.30 | 07/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805041 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,972.30 | 07/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805043 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,615.50 | 07/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805045 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,333.54 | 07/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805727 |
| Principal investigator 1 | Genentech, Inc. | $9,900.00 | 07/23/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211681970 |
| Principal investigator 1 | Genentech, Inc. | $16,582.00 | 07/23/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211681974 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 07/23/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211681976 |
| Principal investigator 1 | Genentech, Inc. | $9,900.00 | 07/23/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211681978 |
| Principal investigator 1 | BioNTech SE | $14,098.00 | 07/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-01 | No dispute reported | 06/30/2026 | 1249012835 |
| Principal investigator 1 | BioNTech SE | $129.00 | 07/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-01 | No dispute reported | 06/30/2026 | 1249012837 |
| Principal investigator 1 | Genentech, Inc. | $76,672.00 | 07/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL | No dispute reported | 06/30/2026 | 1211681946 |
| Principal investigator 1 | Janssen Research & Development, LLC | $22,162.00 | 07/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413672 |
| Principal investigator 1 | Janssen Research & Development, LLC | $32,236.00 | 07/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413991 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,389.60 | 07/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184217635 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $101,250.00 | 07/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805433 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,693.00 | 07/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805705 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,641.00 | 07/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805707 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,641.00 | 07/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805709 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,641.00 | 07/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805711 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,641.00 | 07/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805713 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,334.00 | 07/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805715 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,334.00 | 07/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805717 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,041.00 | 07/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805719 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,000.00 | 07/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805721 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,334.00 | 07/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805723 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,000.00 | 07/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805725 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,333.00 | 07/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388565 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,615.00 | 07/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388567 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,075.00 | 07/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388569 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,210.00 | 07/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388571 |
| Principal investigator 1 | Incyte Corporation | $2,822.00 | 07/18/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611062 |
| Principal investigator 1 | Incyte Corporation | $675.00 | 07/18/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611066 |
| Principal investigator 1 | Incyte Corporation | $2,060.20 | 07/18/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611069 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 07/18/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611083 |
| Principal investigator 1 | Incyte Corporation | $2,822.00 | 07/18/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611090 |
| Principal investigator 1 | Incyte Corporation | $675.00 | 07/18/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611093 |
| Principal investigator 1 | Incyte Corporation | $2,068.00 | 07/18/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611105 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 07/18/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611108 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 07/18/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611112 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 07/18/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240611326 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,075.00 | 07/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184217012 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,075.00 | 07/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184217014 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $491.40 | 07/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184217016 |
| Principal investigator 1 | BioNTech SE | $405.00 | 07/16/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013045 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,709.55 | 07/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804572 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $810.00 | 07/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804574 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,000.00 | 07/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804576 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16,519.95 | 07/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804578 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17,093.70 | 07/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804580 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $675.00 | 07/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388507 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.00 | 07/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388509 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 07/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388511 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 07/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388513 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.00 | 07/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388515 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $57.00 | 07/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388517 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $100.00 | 07/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388635 |
| Principal investigator 1 | PFIZER INC. | $17,841.00 | 07/16/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228847914 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $225.68 | 07/16/2025 | Covered Recipient Physician | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184115625 |
| Principal investigator 1 | ABBVIE INC. | $5,265.00 | 07/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202498282 |
| Principal investigator 1 | ABBVIE INC. | $31,641.86 | 07/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) | No dispute reported | 06/30/2026 | 1202498284 |
| Principal investigator 1 | BeOne Medicines Ltd. | $11,373.12 | 07/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190344618 |
| Principal investigator 1 | BioNTech SE | $176.70 | 07/15/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-01 | No dispute reported | 06/30/2026 | 1249012831 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,403,579.00 | 07/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804570 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,693.00 | 07/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805695 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,693.00 | 07/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805697 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,693.00 | 07/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805699 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,693.00 | 07/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805701 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,693.00 | 07/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805703 |
| Principal investigator 1 | BioNTech SE | $4,532.00 | 07/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013017 |
| Principal investigator 1 | BioNTech SE | $3,686.00 | 07/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013019 |
| Principal investigator 1 | BioNTech SE | $4,018.00 | 07/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013021 |
| Principal investigator 1 | BioNTech SE | $4,030.00 | 07/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013023 |
| Principal investigator 1 | BioNTech SE | $440.00 | 07/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013025 |
| Principal investigator 1 | BioNTech SE | $129.00 | 07/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249013027 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 07/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804552 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 07/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804554 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 07/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804556 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 07/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804558 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 07/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804560 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 07/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804562 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 07/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804564 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 07/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804566 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 07/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804568 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $525,106.00 | 07/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805039 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $304.00 | 07/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388561 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $304.00 | 07/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388563 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 07/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389621 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $540.00 | 07/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389623 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $61.00 | 07/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389625 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $81.00 | 07/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389627 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $332.00 | 07/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389629 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $205.00 | 07/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389685 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $405.00 | 07/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389751 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $121,500.00 | 07/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805429 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $101,250.00 | 07/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805431 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,508.88 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804546 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $29,000.00 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804548 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,384.15 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804550 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $71,478.00 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805389 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $65,225.70 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805391 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,580.00 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805393 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $917.00 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805395 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,727.40 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805397 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,505.63 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805399 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,066.95 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805401 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,424.50 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805403 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $187.00 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805405 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,587.60 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805407 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $457.50 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805409 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,476.50 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805411 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,500.00 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805413 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11,947.00 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805415 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,000.00 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805417 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,973.75 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805419 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,973.75 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805421 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,973.75 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805423 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,616.99 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805425 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805427 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $598.00 | 07/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805693 |
| Principal investigator 1 | ABBVIE INC. | $14,623.00 | 07/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202497900 |
| Principal investigator 1 | BioNTech SE | $10,876.55 | 07/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-01 | No dispute reported | 06/30/2026 | 1249012829 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,384.15 | 07/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804544 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $18.25 | 07/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389607 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 07/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389731 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $20.85 | 07/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389733 |
| Principal investigator 1 | Genentech, Inc. | $17,392.00 | 07/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL | No dispute reported | 06/30/2026 | 1211681948 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,752.54 | 07/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184214290 |
| Principal investigator 1 | BeOne Medicines Ltd. | $47,160.00 | 07/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190336958 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,709.55 | 07/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804536 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,709.55 | 07/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804538 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,384.15 | 07/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804540 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,709.55 | 07/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804542 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $272.00 | 07/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804869 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $100.00 | 07/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804871 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,600.00 | 07/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804873 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,600.00 | 07/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804875 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,758.00 | 07/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804877 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,600.00 | 07/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804879 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,758.00 | 07/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804881 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,758.00 | 07/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804883 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,600.00 | 07/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804885 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,600.00 | 07/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804887 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,758.00 | 07/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804889 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,600.00 | 07/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804891 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,758.00 | 07/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804893 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,758.00 | 07/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804895 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,600.00 | 07/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804897 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,600.00 | 07/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804899 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $40,500.00 | 07/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805387 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $382.44 | 07/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805359 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $671.64 | 07/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805361 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,355.07 | 07/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805363 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,474.98 | 07/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805365 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,562.73 | 07/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805367 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $720.25 | 07/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805369 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $685.68 | 07/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805371 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $370.68 | 07/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805373 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,559.68 | 07/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805375 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,775.25 | 07/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805377 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,625.75 | 07/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805379 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,353.63 | 07/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805381 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $588.28 | 07/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805383 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,800.00 | 07/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805385 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 07/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804532 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 07/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804534 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34,168.50 | 07/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805691 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 07/04/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413692 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 07/04/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413748 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 07/04/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413886 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 07/04/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413997 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $19,207.80 | 07/04/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184212737 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $611.55 | 07/04/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184212739 |
| Principal investigator 1 | ABBVIE INC. | $10,573.14 | 07/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202495117 |
| Principal investigator 1 | ABBVIE INC. | $79,629.75 | 07/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202496019 |
| Principal investigator 1 | ABBVIE INC. | $10,783.80 | 07/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202496021 |
| Principal investigator 1 | ABBVIE INC. | $45,851.42 | 07/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) | No dispute reported | 06/30/2026 | 1202496023 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,694.00 | 07/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804867 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,004.00 | 07/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388559 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $20.00 | 07/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388575 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,615.00 | 07/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388577 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,172.00 | 07/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388595 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $346.00 | 07/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388597 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,763.00 | 07/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388599 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $84.00 | 07/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388601 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,763.00 | 07/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388603 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $279.00 | 07/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388605 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $435.00 | 07/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388607 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,153.00 | 07/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388609 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,091.00 | 07/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388611 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 07/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388639 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,853.00 | 07/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223388643 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 07/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577724 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 07/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577726 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 07/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704041 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704175 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704177 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 07/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704179 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,097.80 | 07/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804851 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,059.00 | 07/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804853 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,500.00 | 07/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804855 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $15,489.00 | 07/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804857 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17,475.00 | 07/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804859 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,694.00 | 07/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804861 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,059.00 | 07/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804863 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,694.00 | 07/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804865 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,810.00 | 07/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805037 |
| Principal investigator 1 | Genentech, Inc. | $28,000.00 | 07/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL | No dispute reported | 06/30/2026 | 1211681944 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,130.65 | 06/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704219 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,789.45 | 06/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704221 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,810.55 | 06/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704223 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,841.60 | 06/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704225 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,417.09 | 06/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704227 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,320.05 | 06/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704229 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,641.66 | 06/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704231 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8,559.00 | 06/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704233 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,291.95 | 06/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704235 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,515.61 | 06/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704237 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,507.37 | 06/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704239 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,638.05 | 06/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704241 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,789.45 | 06/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704243 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,353.05 | 06/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704245 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,891.15 | 06/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704247 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,750.00 | 06/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704249 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,425.48 | 06/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704251 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,966.90 | 06/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704253 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,227.14 | 06/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704255 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,898.00 | 06/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704257 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 06/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704409 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 06/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704411 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 06/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805021 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 06/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805023 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 06/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805025 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 06/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805027 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 06/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805029 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $276.11 | 06/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805031 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.28 | 06/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805033 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,291.30 | 06/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805035 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,250.00 | 06/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220804530 |
| Principal investigator 1 | Genentech, Inc. | $64,528.10 | 06/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211681960 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $509.10 | 06/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704023 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.92 | 06/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704025 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $539.46 | 06/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704027 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 06/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704029 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $244.28 | 06/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704031 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $143.00 | 06/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704033 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.66 | 06/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704035 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $586.00 | 06/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220996752 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $399.60 | 06/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220996754 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $303.16 | 06/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220996794 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $579.42 | 06/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220996796 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $584.00 | 06/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220996798 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $13.30 | 06/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220996800 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $7.10 | 06/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220996802 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $5.52 | 06/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220996804 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1.55 | 06/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220996806 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,525.14 | 06/24/2025 | Non-covered Recipient Entity Valkyrie Global, Inc | A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physicians Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 Treatment | No dispute reported | 06/30/2026 | 1235992021 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,274.12 | 06/24/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184210568 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,306.00 | 06/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804849 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $667.19 | 06/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805357 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,971.00 | 06/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389481 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,064.00 | 06/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389483 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,455.00 | 06/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389591 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 06/18/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240610791 |
| Principal investigator 1 | Incyte Corporation | $2,822.00 | 06/18/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240610795 |
| Principal investigator 1 | Incyte Corporation | $2,068.00 | 06/18/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240610807 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 06/18/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240610815 |
| Principal investigator 1 | BeOne Medicines Ltd. | $13,677.00 | 06/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190331751 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $225.00 | 06/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804847 |
| Principal investigator 1 | ABBVIE INC. | $858.83 | 06/13/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202491421 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $641.00 | 06/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388951 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $236.00 | 06/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388953 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $78.00 | 06/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388955 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 06/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388957 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 06/13/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413834 |
| Principal investigator 1 | ABBVIE INC. | $12,825.00 | 06/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202491197 |
| Principal investigator 1 | BeOne Medicines Ltd. | $62,880.00 | 06/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190337002 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 06/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805003 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 06/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805005 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 06/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805007 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 06/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805009 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $719.26 | 06/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805011 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $347.58 | 06/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805013 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $807.46 | 06/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805015 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $928.16 | 06/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805017 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $820.23 | 06/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805019 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,752.54 | 06/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184206103 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $495.45 | 06/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184206105 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $101.25 | 06/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184206107 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,075.00 | 06/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184206109 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,075.00 | 06/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184206111 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,075.00 | 06/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184206113 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,545.75 | 06/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184206115 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,075.00 | 06/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184206117 |
| Principal investigator 1 | ABBVIE INC. | $29,243.70 | 06/11/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202490829 |
| Principal investigator 1 | ABBVIE INC. | $25,650.00 | 06/11/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202490865 |
| Principal investigator 1 | ABBVIE INC. | $12,825.00 | 06/11/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202490867 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $32.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389369 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $154.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389411 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $32.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389413 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389415 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $300.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389417 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $32.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389419 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $54.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389421 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389423 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $300.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389425 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $263.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389503 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389505 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $84.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389507 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $55.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389509 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $105.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389511 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $205.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389513 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $81.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389515 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $72.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389517 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $405.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389519 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $58.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389521 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $675.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389523 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389525 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $54.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389527 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $42.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389529 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389531 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389533 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389535 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $379.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389537 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389539 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389541 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $61.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389543 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $100.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389545 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,013.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389547 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $57.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389549 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,801.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389551 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,059.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389571 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389583 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389587 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 06/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389603 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $751.82 | 06/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703999 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $776.22 | 06/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704001 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $811.08 | 06/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704003 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,123.24 | 06/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704005 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $752.25 | 06/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704007 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $101.35 | 06/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704009 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $52.97 | 06/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704011 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.30 | 06/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704013 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 06/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389331 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 06/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389333 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $270.00 | 06/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389341 |
| Principal investigator 1 | Incyte Corporation | $263.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240610802 |
| Principal investigator 1 | Incyte Corporation | $2,708.10 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610811 |
| Principal investigator 1 | Incyte Corporation | $61.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610820 |
| Principal investigator 1 | Incyte Corporation | $675.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610824 |
| Principal investigator 1 | Incyte Corporation | $2,709.05 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610829 |
| Principal investigator 1 | Incyte Corporation | $2,822.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610832 |
| Principal investigator 1 | Incyte Corporation | $77.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610836 |
| Principal investigator 1 | Incyte Corporation | $196.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610840 |
| Principal investigator 1 | Incyte Corporation | $101.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610843 |
| Principal investigator 1 | Incyte Corporation | $506.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610846 |
| Principal investigator 1 | Incyte Corporation | $603.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610850 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610854 |
| Principal investigator 1 | Incyte Corporation | $196.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610859 |
| Principal investigator 1 | Incyte Corporation | $1,806.03 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610863 |
| Principal investigator 1 | Incyte Corporation | $101.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610867 |
| Principal investigator 1 | Incyte Corporation | $101.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610869 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610873 |
| Principal investigator 1 | Incyte Corporation | $603.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610877 |
| Principal investigator 1 | Incyte Corporation | $263.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610880 |
| Principal investigator 1 | Incyte Corporation | $2,822.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610883 |
| Principal investigator 1 | Incyte Corporation | $77.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610886 |
| Principal investigator 1 | Incyte Corporation | $196.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610889 |
| Principal investigator 1 | Incyte Corporation | $603.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610897 |
| Principal investigator 1 | Incyte Corporation | $603.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610900 |
| Principal investigator 1 | Incyte Corporation | $603.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610904 |
| Principal investigator 1 | Incyte Corporation | $2,822.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610907 |
| Principal investigator 1 | Incyte Corporation | $55.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610912 |
| Principal investigator 1 | Incyte Corporation | $95.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610919 |
| Principal investigator 1 | Incyte Corporation | $129.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610923 |
| Principal investigator 1 | Incyte Corporation | $129.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610927 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610939 |
| Principal investigator 1 | Incyte Corporation | $2,709.05 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610942 |
| Principal investigator 1 | Incyte Corporation | $603.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610949 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610961 |
| Principal investigator 1 | Incyte Corporation | $196.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610965 |
| Principal investigator 1 | Incyte Corporation | $196.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610968 |
| Principal investigator 1 | Incyte Corporation | $196.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610972 |
| Principal investigator 1 | Incyte Corporation | $101.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610993 |
| Principal investigator 1 | Incyte Corporation | $101.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610997 |
| Principal investigator 1 | Incyte Corporation | $101.00 | 06/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240611000 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $145.33 | 06/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220804999 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $430.10 | 06/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220805001 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $112.00 | 06/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704015 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $242.00 | 06/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704017 |
| Principal investigator 1 | ABBVIE INC. | $6,031.46 | 06/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202488519 |
| Principal investigator 1 | ABBVIE INC. | $76,893.30 | 06/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202489333 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 06/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413730 |
| Principal investigator 1 | BeOne Medicines Ltd. | $31,440.00 | 06/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190330395 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $416.00 | 06/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389111 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $263.00 | 06/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389389 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $405.00 | 06/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389391 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $81.00 | 06/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389601 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 06/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413754 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 06/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413791 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 06/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413803 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 06/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413870 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 06/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413897 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 06/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413922 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,020.00 | 06/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413935 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 06/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413976 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,560.00 | 06/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175414007 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 06/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577720 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 06/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577722 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 06/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703997 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 06/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704167 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 06/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704169 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704171 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704173 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 05/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704405 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 05/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704407 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $835.89 | 05/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805683 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,037.75 | 05/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805685 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $740.02 | 05/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805687 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $660.02 | 05/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805689 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,892.95 | 05/29/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804845 |
| Principal investigator 1 | Genentech, Inc. | $42,181.00 | 05/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211681962 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,191.85 | 05/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184198803 |
| Principal investigator 1 | ABBVIE INC. | $12,825.00 | 05/27/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202486201 |
| Principal investigator 1 | ABBVIE INC. | $25,650.00 | 05/27/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202486203 |
| Principal investigator 1 | ABBVIE INC. | $25,650.00 | 05/27/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202486205 |
| Principal investigator 1 | ABBVIE INC. | $38,475.00 | 05/27/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202486207 |
| Principal investigator 1 | ABBVIE INC. | $14,623.00 | 05/27/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202486209 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 05/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704019 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.00 | 05/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220704021 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $178.90 | 05/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704413 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,131.02 | 05/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704415 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $459.54 | 05/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704417 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $839.50 | 05/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704419 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $56.50 | 05/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704421 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $139.92 | 05/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220996760 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $199.80 | 05/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220996762 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $401.50 | 05/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220996764 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $732.84 | 05/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220996766 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $97.20 | 05/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220996768 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $686.98 | 05/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220996770 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,826.07 | 05/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805681 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $358.34 | 05/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389025 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $518.09 | 05/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389027 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 05/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389557 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $32.00 | 05/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389559 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $97.00 | 05/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389561 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.00 | 05/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389593 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,510.00 | 05/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703973 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,105.00 | 05/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703975 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,105.00 | 05/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703977 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $989.00 | 05/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703979 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $473.00 | 05/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703981 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,306.00 | 05/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703983 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,510.00 | 05/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703985 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,105.00 | 05/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703987 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,105.00 | 05/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703989 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $258.00 | 05/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703991 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $989.00 | 05/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703993 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $33.58 | 05/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804839 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $399.82 | 05/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804841 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $153.36 | 05/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804843 |
| Principal investigator 1 | BeiGene, Ltd. | $4,301.00 | 05/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190320412 |
| Principal investigator 1 | BeiGene, Ltd. | $12,114.12 | 05/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190320976 |
| Principal investigator 1 | BeiGene, Ltd. | $279.00 | 05/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190320980 |
| Principal investigator 1 | BeiGene, Ltd. | $1,518.00 | 05/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190320982 |
| Principal investigator 1 | BeiGene, Ltd. | $198.00 | 05/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190320984 |
| Principal investigator 1 | BeiGene, Ltd. | $11,454.12 | 05/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190320986 |
| Principal investigator 1 | BeiGene, Ltd. | $1,154.08 | 05/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190320988 |
| Principal investigator 1 | BeiGene, Ltd. | $14,976.72 | 05/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190320990 |
| Principal investigator 1 | BeiGene, Ltd. | $198.00 | 05/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190320996 |
| Principal investigator 1 | BeiGene, Ltd. | $16,587.12 | 05/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190320998 |
| Principal investigator 1 | BeiGene, Ltd. | $1,518.00 | 05/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190321000 |
| Principal investigator 1 | BeiGene, Ltd. | $9,900.00 | 05/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190321002 |
| Principal investigator 1 | BeiGene, Ltd. | $279.00 | 05/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190321008 |
| Principal investigator 1 | BeiGene, Ltd. | $1,518.00 | 05/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190321012 |
| Principal investigator 1 | BeiGene, Ltd. | $7,206.24 | 05/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190321014 |
| Principal investigator 1 | BeiGene, Ltd. | $2,383.08 | 05/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190321018 |
| Principal investigator 1 | BeiGene, Ltd. | $12,114.12 | 05/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190321020 |
| Principal investigator 1 | BeiGene, Ltd. | $14,976.72 | 05/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190321022 |
| Principal investigator 1 | BeiGene, Ltd. | $11,373.12 | 05/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190321024 |
| Principal investigator 1 | BeiGene, Ltd. | $11,677.00 | 05/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190325664 |
| Principal investigator 1 | BioNTech SE | $5,571.00 | 05/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012749 |
| Principal investigator 1 | BioNTech SE | $135.00 | 05/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012751 |
| Principal investigator 1 | BioNTech SE | $405.00 | 05/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012753 |
| Principal investigator 1 | BioNTech SE | $405.00 | 05/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012755 |
| Principal investigator 1 | BioNTech SE | $405.00 | 05/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012757 |
| Principal investigator 1 | BioNTech SE | $77.00 | 05/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012759 |
| Principal investigator 1 | BioNTech SE | $405.00 | 05/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012761 |
| Principal investigator 1 | BioNTech SE | $101.00 | 05/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012763 |
| Principal investigator 1 | BioNTech SE | $135.00 | 05/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012983 |
| Principal investigator 1 | BioNTech SE | $5,571.00 | 05/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012985 |
| Principal investigator 1 | BioNTech SE | $5,301.00 | 05/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012987 |
| Principal investigator 1 | BioNTech SE | $405.00 | 05/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012993 |
| Principal investigator 1 | BioNTech SE | $77.00 | 05/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012995 |
| Principal investigator 1 | BioNTech SE | $101.00 | 05/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012997 |
| Principal investigator 1 | BioNTech SE | $154.00 | 05/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012999 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 05/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389553 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $81.00 | 05/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389555 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $32.00 | 05/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389575 |
| Principal investigator 1 | Incyte Corporation | $4,836.00 | 05/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610765 |
| Principal investigator 1 | Incyte Corporation | $2,822.00 | 05/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610769 |
| Principal investigator 1 | Incyte Corporation | $258.00 | 05/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610777 |
| Principal investigator 1 | Incyte Corporation | $675.00 | 05/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610788 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 05/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610798 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 05/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610977 |
| Principal investigator 1 | BeiGene, Ltd. | $31,440.00 | 05/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190323548 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,328.00 | 05/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389311 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,950.00 | 05/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389313 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,210.00 | 05/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389315 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,898.00 | 05/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389317 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,807.00 | 05/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389319 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,898.00 | 05/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389321 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,578.00 | 05/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389323 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,898.00 | 05/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389325 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,210.00 | 05/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389327 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,055.00 | 05/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389329 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,898.00 | 05/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389335 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,148.00 | 05/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389337 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $304.00 | 05/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389339 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,719.00 | 05/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389343 |
| Principal investigator 1 | Genentech, Inc. | $156,735.00 | 05/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211681968 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $30,655.80 | 05/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805679 |
| Principal investigator 1 | Janssen Research & Development, LLC | $149,822.00 | 05/08/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413970 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,752.54 | 05/08/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184193695 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,062.50 | 05/08/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184193697 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $20,629.35 | 05/08/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184193699 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $13,315.05 | 05/08/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184193701 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $14,692.05 | 05/08/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184193703 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,375.00 | 05/08/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184193705 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $19,201.05 | 05/08/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184193707 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $19,819.35 | 05/08/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184193709 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,872.50 | 05/08/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184193711 |
| Principal investigator 1 | ABBVIE INC. | $6,100.92 | 05/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202482873 |
| Principal investigator 1 | ABBVIE INC. | $92,298.15 | 05/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202482875 |
| Principal investigator 1 | ABBVIE INC. | $37,125.00 | 05/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202482927 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389371 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389373 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389375 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389377 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389379 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $379.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389381 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389383 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389385 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389387 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389393 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389395 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,784.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389397 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,404.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389399 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,404.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389401 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389403 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389405 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389407 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389409 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389431 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389435 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389437 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389439 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389445 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,455.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389447 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389449 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,278.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389451 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,801.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389453 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $379.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389455 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389457 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389459 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389461 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389463 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389465 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389467 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389469 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $42.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389471 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $405.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389473 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $263.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389475 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $300.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389477 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $81.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389479 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389485 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $379.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389487 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389489 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,064.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389491 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,455.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389493 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,971.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389495 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389497 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $32.40 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389499 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389501 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389563 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389565 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389567 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389569 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $270.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389573 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389577 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,801.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389579 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389581 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389585 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389589 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,404.00 | 05/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389595 |
| Principal investigator 1 | Incyte Corporation | $1,378.45 | 05/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240610934 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $80,496.90 | 05/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805355 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12,164.00 | 05/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703937 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7,946.00 | 05/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703939 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7,946.00 | 05/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703941 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $790.00 | 05/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703943 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $790.00 | 05/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703945 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $355.00 | 05/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703947 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12,164.00 | 05/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703949 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $145.00 | 05/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703951 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $145.00 | 05/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703953 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $145.00 | 05/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703955 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $145.00 | 05/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703957 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.00 | 05/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703959 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $355.00 | 05/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703961 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,510.00 | 05/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703963 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,105.00 | 05/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703965 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $190.00 | 05/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703967 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $989.00 | 05/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703969 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,105.00 | 05/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703971 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,384.00 | 05/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388943 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,249.00 | 05/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388945 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,384.00 | 05/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388947 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,557.00 | 05/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388949 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $675.00 | 05/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388959 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $294.29 | 05/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388961 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,418.00 | 05/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389095 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $675.00 | 05/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184191877 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $19,144.35 | 05/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184191879 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,375.00 | 05/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184191881 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $13,169.25 | 05/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184191883 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $19,201.05 | 05/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184191885 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $19,819.35 | 05/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184191887 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $19,819.35 | 05/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184191889 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $19,819.35 | 05/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184191891 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $19,819.35 | 05/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184192071 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $19,819.35 | 05/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184192073 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,080.00 | 05/02/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184192075 |
| Principal investigator 1 | BioNTech SE | $97.00 | 05/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012841 |
| Principal investigator 1 | BioNTech SE | $97.00 | 05/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012843 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 05/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577716 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 05/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577718 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 05/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703995 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704163 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704165 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $785.00 | 05/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220704369 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $29,690.35 | 05/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804837 |
| Principal investigator 1 | BeiGene, Ltd. | $31,440.00 | 04/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325228 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,370.21 | 04/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220704371 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.94 | 04/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220704373 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $133.41 | 04/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704397 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,284.19 | 04/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184190613 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 04/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220804997 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $81.62 | 04/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220996786 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $59.94 | 04/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220996788 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $146.00 | 04/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220996790 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $2.76 | 04/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220996792 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.00 | 04/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220804993 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,055.50 | 04/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220804995 |
| Principal investigator 1 | BeiGene, Ltd. | $6,222.00 | 04/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190320416 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.02 | 04/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704399 |
| Principal investigator 1 | BioNTech SE | $3,147.45 | 04/21/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012989 |
| Principal investigator 1 | BioNTech SE | $3,456.00 | 04/21/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT321-02 | No dispute reported | 06/30/2026 | 1249012991 |
| Principal investigator 1 | ABBVIE INC. | $26,611.20 | 04/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202477324 |
| Principal investigator 1 | BeiGene, Ltd. | $13,602.00 | 04/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190320414 |
| Principal investigator 1 | BeiGene, Ltd. | $8,831.00 | 04/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190325658 |
| Principal investigator 1 | BeiGene, Ltd. | $31,440.00 | 04/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190322242 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,239.00 | 04/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805677 |
| Principal investigator 1 | BeiGene, Ltd. | $15,720.00 | 04/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321962 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $51,142.50 | 04/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805675 |
| Principal investigator 1 | BeiGene, Ltd. | $47,160.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321864 |
| Principal investigator 1 | BeiGene, Ltd. | $15,720.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190323888 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,015.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388941 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,368.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388963 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388965 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388967 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388969 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388971 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388973 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388975 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388977 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388979 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388981 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388983 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388985 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388987 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388989 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388991 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388993 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388995 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388997 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388999 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389001 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389003 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389005 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389007 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389009 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389011 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389013 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389015 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389017 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389019 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389021 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389023 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389029 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389031 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389033 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389035 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389037 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389039 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389041 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389043 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389045 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389047 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389049 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389051 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389053 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389055 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389057 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389059 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389061 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389063 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389065 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389067 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389069 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,970.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389071 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,970.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389073 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,468.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389075 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,397.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389077 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,970.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389079 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,418.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389081 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,980.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389083 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389085 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389087 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389089 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389091 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389093 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389097 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,500.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389099 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389101 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389103 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389105 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389107 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389109 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389113 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389427 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389429 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,404.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389433 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389597 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 04/09/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389599 |
| Principal investigator 1 | Incyte Corporation | $750.00 | 04/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610747 |
| Principal investigator 1 | Incyte Corporation | $695.00 | 04/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610751 |
| Principal investigator 1 | Incyte Corporation | $1,750.00 | 04/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610755 |
| Principal investigator 1 | Incyte Corporation | $660.00 | 04/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610761 |
| Principal investigator 1 | Incyte Corporation | $4,000.00 | 04/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610772 |
| Principal investigator 1 | Incyte Corporation | $695.00 | 04/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610780 |
| Principal investigator 1 | Incyte Corporation | $110.00 | 04/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610893 |
| Principal investigator 1 | Incyte Corporation | $3,300.00 | 04/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610931 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 04/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610945 |
| Principal investigator 1 | Incyte Corporation | $110.00 | 04/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610953 |
| Principal investigator 1 | Incyte Corporation | $110.00 | 04/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610958 |
| Principal investigator 1 | Incyte Corporation | $695.00 | 04/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610981 |
| Principal investigator 1 | Incyte Corporation | $660.00 | 04/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610985 |
| Principal investigator 1 | Incyte Corporation | $660.00 | 04/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610989 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20.53 | 04/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704401 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.18 | 04/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704403 |
| Principal investigator 1 | Incyte Corporation | $140.10 | 04/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240610784 |
| Principal investigator 1 | Incyte Corporation | $3,449.00 | 04/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240610916 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $27,065.62 | 04/04/2025 | Non-covered Recipient Entity Valkyrie Global, Inc | A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235992015 |
| Principal investigator 1 | ABBVIE INC. | $19,079.55 | 04/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202469704 |
| Principal investigator 1 | ABBVIE INC. | $104,811.30 | 04/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202469708 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16,990.75 | 04/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804825 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,000.00 | 04/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703935 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $10,010.43 | 04/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220996834 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $10,010.43 | 04/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220996836 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $7,290.00 | 04/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389303 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,210.00 | 04/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389305 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,075.00 | 04/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389307 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,332.50 | 04/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389309 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 04/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389367 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,143.00 | 04/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389441 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 04/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389443 |
| Principal investigator 1 | BeiGene, Ltd. | $12,193.51 | 04/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190320978 |
| Principal investigator 1 | BeiGene, Ltd. | $15,636.72 | 04/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190320992 |
| Principal investigator 1 | BeiGene, Ltd. | $1,357.00 | 04/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190320994 |
| Principal investigator 1 | BeiGene, Ltd. | $2,000.00 | 04/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190321004 |
| Principal investigator 1 | BeiGene, Ltd. | $1,023.00 | 04/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190321006 |
| Principal investigator 1 | BeiGene, Ltd. | $429.00 | 04/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190321010 |
| Principal investigator 1 | BeiGene, Ltd. | $12,356.07 | 04/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190321016 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 04/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577712 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 04/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577714 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 04/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703933 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704159 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704161 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $719.55 | 04/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184180542 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,667.60 | 04/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184180546 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,065.00 | 04/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184180548 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,661.65 | 04/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184180766 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,939.57 | 04/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184180768 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 04/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184180772 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 04/01/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184180774 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,745.55 | 03/31/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704213 |
| Principal investigator 1 | Janssen Research & Development, LLC | $83,790.00 | 03/31/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413679 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11,265.95 | 03/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805349 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,973.80 | 03/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805351 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16,872.97 | 03/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805353 |
| Principal investigator 1 | ABBVIE INC. | $2,067.00 | 03/27/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202466783 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $84.05 | 03/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | PhII in 2nd line pts with Her2+ tumors other than NSCLC | No dispute reported | 06/30/2026 | 1220704375 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $33,981.50 | 03/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804835 |
| Principal investigator 1 | ABBVIE INC. | $3,367.00 | 03/26/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202466188 |
| Principal investigator 1 | ABBVIE INC. | $155.00 | 03/26/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202466193 |
| Principal investigator 1 | ABBVIE INC. | $1,163.00 | 03/26/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202466197 |
| Principal investigator 1 | ABBVIE INC. | $3,421.00 | 03/26/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202466201 |
| Principal investigator 1 | ABBVIE INC. | $221.40 | 03/26/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202466205 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $68.00 | 03/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703855 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $105.00 | 03/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703857 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,086.00 | 03/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703859 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $68.00 | 03/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703905 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $829.00 | 03/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703907 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $675.00 | 03/26/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703909 |
| Principal investigator 1 | Genentech, Inc. | $83,059.80 | 03/26/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211681966 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $612.00 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190338637 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $612.00 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190338640 |
| Principal investigator 1 | BeiGene, Ltd. | $11,896.00 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190325656 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $169.70 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703925 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $199.80 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703927 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20.00 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703929 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14.60 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703931 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $143.12 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704385 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,072.72 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704387 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $279.72 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704389 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704391 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.64 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704393 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $41.00 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704395 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $293.00 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220996744 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $466.40 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220996746 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $199.80 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220996748 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $53.20 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220996750 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $254.55 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220996808 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $209.88 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220996810 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $119.88 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220996812 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $73.00 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220996814 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $21.02 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220996816 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $16.80 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220996818 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $15.50 | 03/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion PANTUMOR-1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours | No dispute reported | 06/30/2026 | 1220996820 |
| Principal investigator 1 | Incyte Corporation | $2,250.00 | 03/24/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610676 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,240.00 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389115 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389117 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,801.00 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389119 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $57.92 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389121 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $185.00 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389123 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389125 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389127 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,801.00 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389129 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389131 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389133 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $379.00 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389135 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389137 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,187.55 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389139 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389141 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $379.00 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389143 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $379.00 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389147 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389149 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389151 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389153 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389155 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $177.00 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389207 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389211 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,801.00 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389213 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $641.00 | 03/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389215 |
| Principal investigator 1 | ABBVIE INC. | $3,553.00 | 03/20/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202465123 |
| Principal investigator 1 | Janssen Research & Development, LLC | $56,969.00 | 03/20/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413949 |
| Principal investigator 1 | BeiGene, Ltd. | $31,440.00 | 03/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190321910 |
| Principal investigator 1 | BioNTech SE | $8,467.35 | 03/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-01 | No dispute reported | 06/30/2026 | 1249012825 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,237.10 | 03/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805669 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $992.30 | 03/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805671 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $500.00 | 03/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805673 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,000.00 | 03/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389345 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,000.00 | 03/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389347 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,500.00 | 03/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389349 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,615.00 | 03/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389351 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 03/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389353 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,210.00 | 03/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389355 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,700.00 | 03/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389357 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,075.00 | 03/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389359 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $379.00 | 03/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389361 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $12,825.00 | 03/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389363 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,333.00 | 03/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389365 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $20,737.34 | 03/19/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184174630 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $60.04 | 03/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704379 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20.53 | 03/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704381 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.18 | 03/17/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC to determine the MTD and the RP2D and to determine the dosing regimen for further development of BI 765049 | No dispute reported | 06/30/2026 | 1220704383 |
| Principal investigator 1 | PFIZER INC. | $15,338.70 | 03/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228859345 |
| Principal investigator 1 | BioNTech SE | $3,402.90 | 03/14/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012939 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $203.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703901 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $68.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703903 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389841 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389843 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389845 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389847 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389849 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389851 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389853 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389855 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389857 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389859 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389861 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $135.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389863 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389865 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $42.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389867 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389869 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389871 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389873 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389875 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389877 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,211.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389879 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,193.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389881 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,410.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389883 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $379.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389885 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389887 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389889 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389891 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,943.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389955 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389957 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389959 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389961 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389963 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389965 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389967 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,801.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389969 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $405.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389973 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $270.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389975 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389977 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389987 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389989 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $978.00 | 03/14/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389991 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 03/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220804991 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $62,433.90 | 03/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805667 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $10,010.43 | 03/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220996832 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,333.06 | 03/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805663 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,333.06 | 03/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805665 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 03/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389911 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 03/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389913 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 03/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389915 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 03/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389917 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 03/12/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389919 |
| Principal investigator 1 | Incyte Corporation | $547.00 | 03/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240610706 |
| Principal investigator 1 | Incyte Corporation | $329.00 | 03/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240610725 |
| Principal investigator 1 | Incyte Corporation | $329.00 | 03/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240610728 |
| Principal investigator 1 | Incyte Corporation | $3,216.30 | 03/12/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240610739 |
| Principal investigator 1 | BeiGene, Ltd. | $31,440.00 | 03/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190323862 |
| Principal investigator 1 | BioNTech SE | $10,562.10 | 03/11/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-01 | No dispute reported | 06/30/2026 | 1249012823 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $18,157.99 | 03/10/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide and Tislelizumab in Induction and With Tislelizumab in Mainte | No dispute reported | 06/30/2026 | 1190312855 |
| Principal investigator 1 | ABBVIE INC. | $25,057.15 | 03/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202460707 |
| Principal investigator 1 | ABBVIE INC. | $51,767.10 | 03/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202460709 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $195.60 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388845 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $126.80 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388847 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388849 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388851 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $250.75 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388853 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $618.60 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388855 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $293.25 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388857 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $78.00 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388859 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.05 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388867 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.55 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388869 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.55 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388871 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.55 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388873 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.55 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388875 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388877 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388879 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388881 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388883 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388885 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388887 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388889 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388891 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388893 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388895 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388897 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388899 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388901 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $166.60 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388909 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388911 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388913 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $112.05 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388915 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388917 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388921 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388923 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388933 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388937 |
| Principal investigator 1 | Amgen Inc. | $241,288.09 | 03/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1246651091 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $394.00 | 03/05/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805661 |
| Principal investigator 1 | BioNTech SE | $2,835.75 | 03/04/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-01 | No dispute reported | 06/30/2026 | 1249012821 |
| Principal investigator 1 | BioNTech SE | $7,038.55 | 03/04/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012937 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $77,513.63 | 03/04/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184156792 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,004.10 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703861 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9,945.00 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703863 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,986.00 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703865 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $790.00 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703867 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $790.00 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703869 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $68.00 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703871 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $101.00 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703873 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $68.00 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703875 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7,946.00 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703877 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7,946.00 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703879 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7,946.00 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703881 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7,946.00 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703883 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7,946.00 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703885 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $790.00 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703887 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $112.00 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703889 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $242.00 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703891 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.00 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703893 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $101.00 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703895 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $790.00 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703897 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,986.00 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703899 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.00 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703911 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,551.00 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389209 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389285 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $412.40 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389287 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389289 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 03/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389291 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 03/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577704 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 03/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577706 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 03/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703853 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704151 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704153 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704215 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $785.00 | 03/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | PhII in 2nd line pts with Her2+ tumors other than NSCLC | No dispute reported | 06/30/2026 | 1220704377 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,232.55 | 02/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704205 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,344.75 | 02/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704207 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $926.25 | 02/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704209 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,622.70 | 02/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704211 |
| Principal investigator 1 | Janssen Research & Development, LLC | $32,362.00 | 02/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413875 |
| Principal investigator 1 | Amgen Inc. | $1,331.92 | 02/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) | No dispute reported | 06/30/2026 | 1246651095 |
| Principal investigator 1 | BeiGene, Ltd. | $7,361.00 | 02/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190320410 |
| Principal investigator 1 | BioNTech SE | $7,959.10 | 02/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-01 | No dispute reported | 06/30/2026 | 1249012819 |
| Principal investigator 1 | BioNTech SE | $270.00 | 02/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012943 |
| Principal investigator 1 | BioNTech SE | $1,979.00 | 02/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012945 |
| Principal investigator 1 | BioNTech SE | $77.00 | 02/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012947 |
| Principal investigator 1 | BioNTech SE | $211.00 | 02/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012949 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,318.50 | 02/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220996738 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $899.10 | 02/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220996740 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $24.00 | 02/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220996742 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $339.40 | 02/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220996858 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $182.50 | 02/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220996860 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $7.30 | 02/25/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220996862 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,453.40 | 02/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184155620 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,092.15 | 02/25/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184155622 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,742.00 | 02/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220804985 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 02/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220804987 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $25,176.15 | 02/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220804989 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,981.95 | 02/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220804979 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 02/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220804981 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,914.00 | 02/22/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220804983 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $706.33 | 02/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703815 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $68.00 | 02/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703817 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $105.00 | 02/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703819 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $155.00 | 02/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703821 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $68.00 | 02/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703823 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $101.00 | 02/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703825 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,658.00 | 02/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703827 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $101.00 | 02/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703829 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $338.00 | 02/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703831 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $42.00 | 02/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703833 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $68.00 | 02/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703835 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $68.00 | 02/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703837 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $236.00 | 02/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703839 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,510.00 | 02/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703841 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,105.00 | 02/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703843 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,105.00 | 02/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703845 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $989.00 | 02/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703847 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.00 | 02/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703849 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.30 | 02/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220804975 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,093.00 | 02/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220804977 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 02/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389921 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 02/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389923 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 02/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389925 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 02/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389927 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 02/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389929 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 02/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389931 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 02/19/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389981 |
| Principal investigator 1 | BeiGene, Ltd. | $340.00 | 02/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190324818 |
| Principal investigator 1 | BeiGene, Ltd. | $785.00 | 02/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190324822 |
| Principal investigator 1 | BeiGene, Ltd. | $966.08 | 02/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190324824 |
| Principal investigator 1 | BeiGene, Ltd. | $16,839.00 | 02/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190325654 |
| Principal investigator 1 | BeiGene, Ltd. | $1,980.00 | 02/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190325686 |
| Principal investigator 1 | BeiGene, Ltd. | $2,614.44 | 02/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190325688 |
| Principal investigator 1 | BeiGene, Ltd. | $2,385.00 | 02/18/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190325690 |
| Principal investigator 1 | PFIZER INC. | $28,566.00 | 02/18/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228859338 |
| Principal investigator 1 | PFIZER INC. | $17,407.32 | 02/18/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228859349 |
| Principal investigator 1 | PFIZER INC. | $18,417.48 | 02/18/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228859356 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $322.75 | 02/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220804971 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $899.10 | 02/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220804973 |
| Principal investigator 1 | BeiGene USA, Inc. | $1,008.00 | 02/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190321494 |
| Principal investigator 1 | BeiGene USA, Inc. | $462.00 | 02/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190321496 |
| Principal investigator 1 | BeiGene USA, Inc. | $733.00 | 02/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190321498 |
| Principal investigator 1 | BeiGene USA, Inc. | $858.00 | 02/11/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190321500 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,699.20 | 02/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations | No dispute reported | 06/30/2026 | 1220805659 |
| Principal investigator 1 | Genentech, Inc. | $90,155.00 | 02/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211681964 |
| Principal investigator 1 | BeiGene, Ltd. | $25,838.16 | 02/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190322032 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $29,673.90 | 02/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220805347 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,500.00 | 02/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389173 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,980.00 | 02/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389185 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,249.00 | 02/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389187 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,970.00 | 02/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389189 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,015.00 | 02/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389193 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,647.00 | 02/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389197 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,557.00 | 02/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389199 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,557.00 | 02/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389201 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,397.00 | 02/07/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389205 |
| Principal investigator 1 | ABBVIE INC. | $37,125.00 | 02/06/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | M22-128 - A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) | No dispute reported | 06/30/2026 | 1202449875 |
| Principal investigator 1 | BioNTech SE | $3,444.70 | 02/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-01 | No dispute reported | 06/30/2026 | 1249012817 |
| Principal investigator 1 | BioNTech SE | $8,959.45 | 02/05/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012935 |
| Principal investigator 1 | BeiGene, Ltd. | $549.56 | 02/04/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190324820 |
| Principal investigator 1 | Janssen Research & Development, LLC | $35,450.00 | 02/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175413797 |
| Principal investigator 1 | PFIZER INC. | $3,039.00 | 02/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228859334 |
| Principal investigator 1 | PFIZER INC. | $12,567.66 | 02/03/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228859482 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 02/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577700 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 02/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577702 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703851 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704147 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704149 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704203 |
| Principal investigator 1 | AstraZeneca UK Limited | $57,039.00 | 01/31/2025 | Non-covered Recipient Entity VALKYRIE GLOBAL, INC | a phase 2,open label study to evaluate the safety,tolerability,pharmacokinetics,immunogenicity,and antitumor activity of volrustomig priming regimen in combination with other anticancer agents in participants with solid tumors evolve 01 | No dispute reported | 06/30/2026 | 1185552415 |
| Principal investigator 1 | BeiGene, Ltd. | $47,160.00 | 01/30/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190325320 |
| Principal investigator 1 | BioNTech SE | $5,722.80 | 01/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012933 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $69,933.35 | 01/29/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184150046 |
| Principal investigator 1 | ABBVIE INC. | $76.54 | 01/28/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202441722 |
| Principal investigator 1 | BeiGene, Ltd. | $7,056.00 | 01/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190320408 |
| Principal investigator 1 | BeiGene, Ltd. | $10,749.00 | 01/28/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1190325652 |
| Principal investigator 1 | Amgen Inc. | $189,306.93 | 01/27/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy | No dispute reported | 06/30/2026 | 1246651098 |
| Principal investigator 1 | BeiGene, Ltd. | $600.00 | 01/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma | No dispute reported | 06/30/2026 | 1190320104 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $373.34 | 01/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703913 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $199.80 | 01/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703915 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $255.50 | 01/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703917 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $122.14 | 01/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703919 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $70.00 | 01/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703921 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $27.74 | 01/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703923 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $33,981.50 | 01/27/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804833 |
| Principal investigator 1 | BeiGene, Ltd. | $15,720.00 | 01/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190323642 |
| Principal investigator 1 | BeiGene, Ltd. | $1,439.81 | 01/24/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190323644 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $10,010.43 | 01/23/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220996830 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $144,975.04 | 01/23/2025 | Non-covered Recipient Entity Valkyrie Global, Inc | A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors | No dispute reported | 06/30/2026 | 1235992017 |
| Principal investigator 1 | Incyte Corporation | $129.00 | 01/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610673 |
| Principal investigator 1 | Incyte Corporation | $129.00 | 01/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610699 |
| Principal investigator 1 | Incyte Corporation | $675.00 | 01/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610702 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 01/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610710 |
| Principal investigator 1 | Incyte Corporation | $2,916.00 | 01/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610713 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 01/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610718 |
| Principal investigator 1 | Incyte Corporation | $3,040.00 | 01/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610722 |
| Principal investigator 1 | Incyte Corporation | $2,822.00 | 01/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610732 |
| Principal investigator 1 | Incyte Corporation | $2,822.00 | 01/22/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors | No dispute reported | 06/30/2026 | 1240610736 |
| Principal investigator 1 | BeiGene, Ltd. | $3,132.00 | 01/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190320406 |
| Principal investigator 1 | BioNTech SE | $3,433.30 | 01/21/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012931 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,975.50 | 01/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804827 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,825.00 | 01/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804829 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,797.45 | 01/21/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials Inc | DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | No dispute reported | 06/30/2026 | 1220804831 |
| Principal investigator 1 | PFIZER INC. | $998.00 | 01/21/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228859502 |
| Principal investigator 1 | PFIZER INC. | $3,039.00 | 01/21/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 2 BASKET STUDY OF DISITAMAB VEDOTIN IN ADULT SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS THAT EXPRESS HER2 | No dispute reported | 06/30/2026 | 1228859512 |
| Principal investigator 1 | BeiGene, Ltd. | $15,720.00 | 01/20/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia | No dispute reported | 06/30/2026 | 1190323808 |
| Principal investigator 1 | BioNTech SE | $6,510.35 | 01/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-01 | No dispute reported | 06/30/2026 | 1249012815 |
| Principal investigator 1 | BioNTech SE | $1,072.15 | 01/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-01 | No dispute reported | 06/30/2026 | 1249012827 |
| Principal investigator 1 | BioNTech SE | $8,491.10 | 01/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012929 |
| Principal investigator 1 | Incyte Corporation | $329.00 | 01/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240610680 |
| Principal investigator 1 | Incyte Corporation | $329.00 | 01/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240610683 |
| Principal investigator 1 | Incyte Corporation | $3,449.00 | 01/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240610686 |
| Principal investigator 1 | Incyte Corporation | $3,449.00 | 01/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240610691 |
| Principal investigator 1 | Incyte Corporation | $2,882.30 | 01/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240610695 |
| Principal investigator 1 | Incyte Corporation | $329.00 | 01/17/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS | A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | No dispute reported | 06/30/2026 | 1240610743 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 01/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389829 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 01/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389893 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 01/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389895 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 01/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389897 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 01/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389899 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 01/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389901 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 01/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389903 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 01/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389905 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 01/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389907 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,818.00 | 01/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389909 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,724.00 | 01/15/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389971 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,620.00 | 01/13/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389177 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388755 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388757 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $74.70 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388759 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $74.70 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388761 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $74.70 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388763 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $74.70 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388765 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $41.70 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388767 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $41.70 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388769 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388771 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388773 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $41.70 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388775 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388777 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388779 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388781 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $41.70 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388783 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $41.70 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388785 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388787 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388789 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388791 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388793 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388795 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388797 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388799 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388801 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388803 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388805 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388807 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388809 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388811 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388813 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388815 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388817 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388819 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388821 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388823 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388825 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388827 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388829 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388831 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $195.60 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388833 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $195.60 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388835 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388837 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388839 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388841 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388843 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $77.50 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388861 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $77.50 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388863 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $77.50 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388865 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $13.65 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388903 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $515.50 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388905 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $345.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388907 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $41.70 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388919 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388925 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $567.05 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388927 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $77.50 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388929 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388931 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $100.30 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388935 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/10/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223388939 |
| Principal investigator 1 | BioNTech SE | $5,535.00 | 01/09/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012941 |
| Principal investigator 1 | BeiGene, Ltd. | $15,120.00 | 01/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190322054 |
| Principal investigator 1 | BeiGene, Ltd. | $25,838.16 | 01/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | No dispute reported | 06/30/2026 | 1190322056 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,970.00 | 01/08/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-324 | No dispute reported | 06/30/2026 | 1223389145 |
| Principal investigator 1 | Amgen Inc. | $27,494.00 | 01/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1246651102 |
| Principal investigator 1 | BioNTech SE | $6,367.85 | 01/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-01 | No dispute reported | 06/30/2026 | 1249012813 |
| Principal investigator 1 | BioNTech SE | $19,281.20 | 01/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | BNT327-02 | No dispute reported | 06/30/2026 | 1249012927 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $48,936.00 | 01/07/2025 | Non-covered Recipient Entity VALKYRIE CLINICAL TRIALS INC | A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1184146206 |
| Principal investigator 1 | BeiGene, Ltd. | $2,240.00 | 01/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1190320064 |
| Principal investigator 1 | BeiGene, Ltd. | $3,360.00 | 01/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1190324202 |
| Principal investigator 1 | BeiGene, Ltd. | $603.00 | 01/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1190324212 |
| Principal investigator 1 | BeiGene, Ltd. | $2,904.00 | 01/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1190324332 |
| Principal investigator 1 | BeiGene, Ltd. | $3,521.00 | 01/06/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials, Inc | AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1190324340 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,105.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703771 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $989.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703773 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,160.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703775 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $312.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703777 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $473.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703779 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $725.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703781 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,777.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703783 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,878.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703785 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $790.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703787 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,510.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703789 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,105.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703791 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,105.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703793 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $725.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703795 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $989.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703797 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,777.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703799 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $408.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703801 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,028.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703803 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,028.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703805 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,028.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703807 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,510.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703809 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,105.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703811 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $379.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389831 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,818.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389833 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389835 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389837 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,943.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389839 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389933 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389935 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389937 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389939 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,801.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389941 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389943 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389945 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,500.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389947 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389949 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,188.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389951 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $379.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389953 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,943.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389979 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,185.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389983 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,725.00 | 01/03/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS7300-203 | No dispute reported | 06/30/2026 | 1223389985 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $41.70 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389217 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $41.70 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389219 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389221 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $41.70 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389223 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $41.70 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389225 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389227 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4.40 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389229 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389231 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389233 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389235 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389237 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389239 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389241 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389243 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $75.00 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389245 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.40 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389247 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $74.50 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389249 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $257.75 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389251 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4.25 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389253 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $120.75 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389255 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $9.75 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389257 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389259 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389261 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389263 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389265 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389267 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389269 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389271 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.25 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389273 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $50.15 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389275 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389277 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389279 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389281 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $20.85 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389283 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389293 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389295 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $41.70 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389297 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $20.85 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389299 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2.20 | 01/02/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | DS3201-330 | No dispute reported | 06/30/2026 | 1223389301 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 01/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577708 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 01/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577710 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 01/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220703813 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704155 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | Phase Ia, first in human open label dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours | No dispute reported | 06/30/2026 | 1220704157 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Valkyrie Clinical Trials | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220704217 |